Fasudil oral formulation with ion exchange resin

By using ion exchange resins and taste masking agents in pharmaceutical compositions to mask the bitterness of rho kinase inhibitors, the problem of medication adherence, especially in elderly patients with dysphagia, is solved, and the palatability of medications for patients with neurodegenerative diseases is improved.

CN118922193APending Publication Date: 2024-11-08WOOLSEY PHARMACEUTICALS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380029420.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-02-17
Filing Date
2023-02-17
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

Elderly people, especially those with neurodegenerative diseases, find it difficult to adhere to a consistent medication regimen. In particular, patients with dysphagia complicate compliance with multi-drug regimens, and strong aversion to certain tastes and textures becomes a major obstacle to the palatability of drug formulations.

Method used

An oral pharmaceutical composition is provided, comprising a rho kinase inhibitor such as fasudil and an ion exchange resin to mask its bitterness, and to improve its palatability by masking agents such as sweeteners and flavoring agents, suitable for use by patients with dysphagia, and in dosage forms including solid and liquid forms.

Benefits of technology

It improves medication adherence in patients with neurodegenerative diseases and enhances palatability by masking the bitter and numbing taste of rho kinase inhibitors, making it suitable for patients with dysphagia.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118922193A_ABST
    Figure CN118922193A_ABST
Patent Text Reader

Abstract

Provided is an oral pharmaceutical composition which may include an rho kinase inhibitor, such as fasudil, having a bitter taste, a pharmaceutically acceptable salt thereof, a hydrate thereof, a prodrug thereof, a substituted derivative thereof, or a metabolite thereof, or any combination thereof; and an ion exchange resin. The ion exchange resin may partially or completely mask the bitter taste of the rho kinase inhibitor, thereby making the composition more palatable. The composition may include a solid dosage form and / or a liquid dosage form. The solid dosage form may include a powder, a particulate, a tablet, or a capsule, or any combination thereof. The composition may be present in a unit dose, for example, in an amount sufficient to treat a neurodegenerative disease. A method of treating the neurodegenerative disease with the oral pharmaceutical composition is provided. The method can ameliorate the symptoms of neurodegenerative disease.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Cross-reference to related applications

[0002] This international application claims the benefit of U.S. Provisional Patent Application No. 63 / 311,272, filed on February 17, 2022, which is incorporated herein by reference in its entirety. Background Art

[0003] Elderly people, especially those with neurodegenerative diseases, may have difficulty adhering to a consistent medication regimen. Compliance may be further complicated for patients receiving a multi-drug regimen and for patients who experience dysphagia. Strong aversion to certain tastes and mouthfeel and sensory perceptions may be a significant barrier for such patients. Considering the large number of variables associated with both the contents of the drug formulation and the patient, making a drug formulation with an unpleasant taste palatable may require overcoming significant obstacles. Summary of the invention

[0004] Provided is an oral pharmaceutical composition that may include: a rho kinase inhibitor, a pharmaceutically acceptable salt thereof, a hydrate thereof, a prodrug thereof, a substituted derivative thereof, or a metabolite thereof, or any combination thereof, wherein the rho kinase inhibitor has a bitter taste; and an ion exchange resin. The rho kinase inhibitor may include, for example, fasudil, such as hexahydro-1-(5-isoquinolinesulfonyl)-1H-1,4-diazepine monohydrochloride hemihydrate, or a metabolite thereof, or both. For example, the metabolite may be hydroxyfasudil. The ion exchange resin may partially or completely mask the bitter taste of the rho kinase inhibitor. The bitter taste may be accompanied by a numbing taste, or the numbing taste may be present without a bitter taste. The ion exchange resin may be similarly effective in masking the numbing taste. The ion exchange resin may be a first taste masking agent, and the oral pharmaceutical composition may further include a second taste masking agent. The first taste masking agent may be a bitter taste masking agent, and the second taste masking agent may be a taste masking agent, such as a non-bitter taste masking agent. The second taste masking agent may include, for example, one or both of a sweetener and a flavoring agent. The oral pharmaceutical composition may include a coating. The oral pharmaceutical composition may include a solid dosage form or a liquid dosage form, or both. The solid dosage form may include a powder, a granule, a tablet or a capsule, or any combination thereof. The granule, the powder or both may be provided as a sprinkle. A pharmaceutically acceptable taste masking composition is disclosed, comprising, for example, a rho kinase inhibitor (such as fasudil (including salts and hydrates)), at least one resin present as a taste masking agent, and at least one pharmaceutically acceptable excipient.

[0005] The oral pharmaceutical composition of the present disclosure can be formulated so that the rho kinase inhibitor is present in an amount sufficient to treat a neurodegenerative disease. Neurodegenerative diseases can include, for example, Alzheimer's disease, vascular dementia, amyotrophic lateral sclerosis (ALS), motor neuron disease (including amyotrophic lateral sclerosis (ALS), progressive bulbar palsy (PBP), pseudobulbar palsy, progressive muscular atrophy (PMA), primary lateral sclerosis (PLS), spinal muscular atrophy (SMA) and monolimbic muscular atrophy (MMA) and some rare variants similar to ALS), Parkinson's disease, Huntington's disease, multiple sclerosis, progressive supranuclear palsy (PSP) or corticobasal syndrome (CBS), or any combination thereof. The present disclosure provides a method for treating a neurodegenerative disease. The method can include administering an oral pharmaceutical composition of the present disclosure to a patient in one or more doses in an amount sufficient to treat the neurodegenerative disease. A method is also provided, comprising administering an oral pharmaceutical composition of the present disclosure to a patient in one or more doses in an amount sufficient to improve the symptoms of a neurodegenerative disease. For example, symptoms may include wandering, restlessness, cognitive impairment, anxiety, muscle weakness and / or muscle degeneration, sleep disorders, dyspnea, sleep apnea, depression, mental problems, etc., or any combination thereof. The oral pharmaceutical composition may be administered, for example, by mixing the composition with food or beverage or both.

[0006] The present disclosure also encompasses methods of making the compositions of the present disclosure. The present disclosure also provides uses of rho kinase inhibitors for making the compositions of the present disclosure, for example, for treating one or more neurodegenerative diseases. The present disclosure further provides uses of rho kinase inhibitors for treating one or more neurodegenerative diseases in the compositions of the present disclosure. BRIEF DESCRIPTION OF THE DRAWINGS

[0007] Figure 1 A graph depicting the percentage of fasudil bound to the sulfonate resin as a function of pH is shown.

[0008] Figure 2 Graph depicting the percent binding of Fasudil to Polacrilin IRP 64 resin as a function of pH.

[0009] Figure 3 A graph depicting the dissolution profile of a spray containing fasudil over time under two different conditions.

[0010] Figure 4 Depicted is the dissolution of fasudil and IRP 64 resin complex USPII, 900 mL, 50 rpm. DETAILED DESCRIPTION

[0011] The present disclosure is not limited to the specific embodiments of the present disclosure described herein, as changes may be made to the specific embodiments and still fall within the scope of the present disclosure and claims. Terms are used in a non-restrictive manner and are intended to describe specific embodiments. Unless the context clearly indicates otherwise, the singular forms "a", "an", and "the" include plural referents. Unless otherwise defined, all technical and scientific terms have the same meaning as commonly understood by those of ordinary skill in the art to which the present disclosure belongs.

[0012] As used herein, when the name of a specific compound is used, unless otherwise expressly stated, the name should be interpreted as including all forms of the compound, including the free base (or acid), any salt, any hydrate, any hydrophobic ion pair, any polymorph, and any combination thereof. Thus, when fasudil or hydroxyfasudil (M3) is used, for example, it should be understood that these terms include the free base, any salt, any hydrate, any hydrophobic ion pair, any polymorph, and any combination thereof, unless otherwise stated.

[0013] The present disclosure is based in part on the unexpected discovery that certain rho kinase inhibitors, including fasudil hydrochloride and the major metabolite hydroxyfasudil (M3), have a very unpleasant numbing and bitter taste. There is a need for pharmaceutical compositions containing agents that mask this taste, which is expected to increase patient compliance. Therefore, a taste-masking composition is provided, which can include at least a bitter rho kinase inhibitor and a taste-masking agent. The taste-masking composition can be in any oral dosage form, including liquids (e.g., thickened solutions or suspensions) or solids (tablets, mini-tablets, capsules, powders or microparticles). Exemplary forms of taste-masking compositions include solutions, suspensions, gels, pectins, films, tablets (coated and uncoated), mini-tablets (coated and uncoated; containing 5 mg or less active ingredient), bilayer tablets (coated and uncoated), slurries, capsules, microparticles (coated and uncoated), dissolving tablets, multi-particulates, microparticles, powders and sprays. As used herein, a dysphagia-friendly formulation is a formulation suitable for administration to patients with dysphagia. Conventional sized tablets and capsules (e.g., containing at least 10 mg of active ingredient) are not considered dysphagia-friendly because people with dysphagia will have difficulty swallowing them. Examples of dysphagia-friendly formulations include thickened liquids and solid formulations that can be combined with food, such as granules or sprinkles.

[0014] In some cases, conventional film coatings (usually containing wax, cellulose, polyvinyl alcohol or similar bases applied in a thin layer) whose thickness and / or persistence are not enough to mask the taste are not considered to be taste-masked preparations in the absence of additional taste-masking agents. These films are mainly used to improve appearance and fragility, but if applied to patients with dysphagia, they will be released in the oral cavity due to swallowing problems and delays. In addition, when patients have dysphagia, it is often necessary to add the drug to soft food (e.g., yogurt, applesauce, etc.), which also provides the opportunity for such coatings to release active ingredients. Therefore, such films are not suitable for treating patients with dysphagia because they expose patients to any disgusting taste. Therefore, preparations with such simple film coatings (e.g., coated tablets, beads or microparticles) and capsules containing otherwise unmasked ingredients are excluded. In other words, film-coated preparations and capsules (soft or hard) whose thickness and / or persistence are not enough to mask the taste and do not contain additional taste-masking agents or mechanisms are excluded from the compositions of the present invention unless they are further taste-masked according to the present disclosure.

[0015] Any rho kinase inhibitor or combination of rho kinase inhibitors may be used. Reference to a rho kinase inhibitor includes compounds that can directly inhibit rho kinase in the composition, as well as compounds that become rho kinase inhibitors after one or more modifications (e.g., metabolic modification by one or more enzymes or other processes) after administration. The rho kinase inhibitor may inhibit rho kinase using any relevant mechanism. For example, the inhibition may be competitive, non-competitive, reversible or reversible, or any combination thereof. The rho kinase inhibitor may be the only active pharmaceutical ingredient (API) in the composition, or one or more additional APIs may be present in the composition. Thus, coated tablets and capsules containing otherwise untaste-masked ingredients are excluded, provided that mini tablets containing less than 5 mg of active ingredient are not excluded.

[0016] Rho kinase inhibitors can inhibit one or more types of rho kinases. Rho kinases are typically serine / threonine kinases. Examples of rho kinases include rho kinase 1 (rho-associated coiled-coil-containing protein kinase 1, ROCK1, p160-ROCK) and rho kinase 2 (rho-associated coiled-coil-containing protein kinase 2, ROCK2). Rho kinase inhibitors can inhibit ROCK1 or ROCK2 or both. The rho kinase inhibited can be human rho kinase, mammalian rho kinase or vertebrate rho kinase, or any combination thereof. Rho kinase inhibitors can inhibit human rho kinase exclusively, or can also inhibit one or more rho kinase homologs in other species.

[0017] The rho kinase inhibitor may include a bitter rho kinase inhibitor, a pharmaceutically acceptable salt thereof, a hydrate thereof, a prodrug thereof, a substituted derivative thereof, or a metabolite thereof, or any combination thereof. The rho kinase inhibitor may include one or more of an isoquinoline ring, a sulfonyl group, and a homopiperazine ring, or one or more equivalent structural parts. For example, the rho kinase inhibitor may include fasudil, a pharmaceutically acceptable salt thereof, a hydrate thereof, a prodrug thereof, a substituted derivative thereof, or a metabolite thereof, or any combination thereof. The rho kinase inhibitor may be in a crystalline form or an amorphous form or both. Any polymorph or combination of polymorphs of the rho kinase inhibitor may be used. Pseudopolymorphs may be used.

[0018] Fasudil includes an isoquinoline ring, which is connected to a homopiperazine ring by a sulfonyl group. Isoquinoline derivatives, such as fasudil, its active metabolites hydroxyfasudil (M3), dimethylfasudil and rosudil, are a class of ROCK inhibitors that can be used. Other ROCK inhibitors are based on 4-aminopyridine structures, for example, Y-27632 (Yoshitomi Pharmaceutical). Other ROCK inhibitors that can be used include, for example, indazole, pyrimidine, pyrrolopyridine, pyrazole, benzimidazole, benzothiazole, benzothiophene, benzamide, aminofuran, quinazoline or boron derivatives, or any combination thereof. Some exemplary ROCK inhibitors are shown below:

[0019]

[0020] Other examples of isoquinoline derived ROCK inhibitors include, for example, dimethyl fasudil and rosudil. Fasudil may exist in the form of a free base or a salt, and may be in the form of a hydrate, such as a hemihydrate. Unless otherwise indicated, references to rho kinase inhibitors apply equally to their free acids or free bases, salts, hydrates, polymorphs and prodrug derivatives. Fasudil may be in the form of hexahydro-1-(5-isoquinolinesulfonyl)-1H-1,4-diazepine monohydrochloride hemihydrate:

[0021]

[0022] In vivo, fasudil undergoes hepatic metabolism to its active metabolite, hydroxyfasudil (also known as M3). Fasudil is substantially converted to its 1-hydroxy (M3) metabolite in vivo. M3 exists in the form of two tautomers, as depicted below:

[0023]

[0024] Rho kinase inhibitors (e.g., fasudil) include pharmaceutically acceptable salts and hydrates. Salts can be formed by reaction with inorganic acids, organic acids, or both. Examples of suitable acids include hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, nitric acid, phosphoric acid, acetic acid, maleic acid, maleic acid, maleic acid, oxalic acid, oxalic acid, tartaric acid, malic acid, mandelic acid, trifluoroacetic acid, pantothenic acid, methanesulfonic acid, or p-toluenesulfonic acid, or any combination thereof.

[0025] The ion exchange resin may include a cation exchange resin, an anion exchange resin or an amphoteric ion exchange resin, or any combination thereof. The ion exchange resin may include a single type of functional group. A single type of ion exchange resin may be used, or a combination of different ion exchange resins may be used. Different ion exchange resins may work synergistically. The ion exchange resin may include, for example, a plurality of different functional groups with different pKa. The bitter masking agent may include a cation exchange resin. A single type of cation exchange resin may be used, or a combination of different cation exchange resins may be used. Different cation exchange resins may work synergistically. The cation exchange resin may include a salt of a polymer having a carboxylic acid functional group. The cation exchange resin may include a weak acid or a salt thereof. The cation exchange resin may include a strong acid or a salt thereof. The cation exchange resin may include a copolymer of methacrylic acid or styrene and divinylbenzene. The cation may include a cross-linked polymer. Examples of cation exchange resins include AMBERLITE IRP 64 (polacrylin, DuPont) [polymer of 2-methyl-2-acrylic acid and divinylbenzene], AMBERLITE IRP 69 (DuPont) (sulfonated copolymer of styrene and divinylbenzene), AMBERLITE IRP 88 (polacrylin potassium, DuPont) [polymer of 2-methyl-2-acrylic acid potassium salt and divinylbenzene], INDION 204 (Ion Exchange, Mumbai, India) and INDION 234 (Ion Exchange, Mumbai, India). Polacrilin resin (AMBERLITE IRP-64 or polychloride) can be prepared by copolymerization of methacrylic acid and divinylbenzene (DVB). Polacrilin potassium (AMBERLITE IRP-88) can then be produced by neutralizing the resin with potassium hydroxide. Other salts of polacrilin can be produced and used, for example, sodium hydroxide can be used to produce polacrilin sodium. Some examples of ion exchange resins are shown in Table A.

[0026] Table A

[0027]

[0028] Combinations of two or more ion exchange resins may be used. For example, two, three, four, five, six, seven, eight, nine, ten or more different ion exchange resins may be used. When different ion exchange resins are used, the different ion exchange resins may all be cation exchange resins, or all be anion exchange resins, or all be amphoteric ion exchange resins, or any combination of different classes of ion exchange resins. If two or more different ion exchange resins are employed, the ratio between any two different ion exchange resins (e.g., the weight ratio between the first ion exchange resin and the second ion exchange resin) can be about 1:100 to about 1:1, about 1:50 to about 1:25, about 1:25 to about 1:10, about 1:10 to about 1:5, about 1:5 to about 1:2.5, about 100:1 to about 1:1, about 50:1 to about 25:1, about 25:1 to about 10:1, about 5:1 to about 2.5:1, about 1.5:1 to about 3:1, about 2.0:1 to about 2.7:1, or about 2.5:1, or any intervening ratio, or any intervening range.

[0029] The composition may include any suitable amount of the rho kinase inhibitor and the ion exchange resin. The composition may include any suitable weight ratio of the ion exchange resin to the rho kinase inhibitor, for example, the weight ratio of the taste masking agent to the rho kinase inhibitor may be about 1:100 to about 1:1, about 1:50 to about 1:25, about 1:25 to about 1:10, about 1:10 to about 1:5, 10:1 to about 1:10, about 1:5 to about 1:2.5, about 100:1 to about 1:1, about 50:1 to about 25:1, about 25:1 to about 10:1, about 5:1 to about 2.5:1, about 1.5:1 to about 3:1, about 2.0:1 to about 2.7:1, or about 2.5:1, or any intermediate ratio, or any intermediate range. For example, the weight ratio of the rho kinase inhibitor to the taste masking agent can be about 1:1 to about 1:10, about 1:2 to about 1:9, about 1:3 to about 1.6.5, about 1:3.5 to about 1:4, about 1:3.5 to about 1:4.5, about 1:3.3 to about 1:3.6, about 1:3.6 to about 1:3.9, about 1:4 to about 1:6, about 1:4 to about 1:4.5, about 1:4.2 to about 1:4.7, about 1:4.5 to about 1.5.5, about 1:4.5 to about 1:5, about 10:1 to about 1:10, or any intervening ratio, or any intervening range. For example, the rho kinase inhibitor can include fasudil, and the taste masking agent can include a resin that can bind to fasudil.

[0030] The ion exchange resin can act as a taste masking agent, such as a bitter masking agent. The ion exchange resin can partially or completely mask the bitter taste of the rho kinase inhibitor. The ion exchange resin can be a first taste masking agent, and the oral pharmaceutical composition can further include a second taste masking agent. The first taste masking agent can be a bitter masking agent, and the second taste masking agent can be a taste masking agent such as a non-bitter masking agent. Both the first taste masking agent and the second taste masking agent can be bitter masking agents. The second taste masking agent can include, for example, one or both of a sweetener and a flavoring agent.

[0031] As used herein, a "taste masking agent" is a pharmaceutically acceptable agent that can mask the bitter taste of a rho kinase inhibitor, other unpleasant tastes present in an oral pharmaceutical composition, or any combination thereof. One or more taste masking agents can be present in an oral pharmaceutical composition. When more than one taste masking agent is present, the taste masking agents can act by the same or different mechanisms to mask the bitter taste of the rho kinase inhibitor, or other unpleasant tastes present in the oral pharmaceutical composition, or both. Multiple taste masking agents can act synergistically. Taste masking agents can directly target the bitter taste of a rho kinase inhibitor, for example by binding to a rho kinase inhibitor or blocking a patient's bitter taste receptors. Such taste masking agents that directly target bitterness can be referred to as bitter masking agents. Taste masking agents can indirectly target the bitter taste of a rho kinase inhibitor by distracting the patient from the perception of bitterness, such as using sweeteners or flavoring agents, or both. Taste masking can be partial or complete. The taste masking agent can be present in the composition in an amount sufficient to substantially neutralize the bitter taste. Substantially neutralizing can be substantially completely neutralizing the bitter taste, or the bitter taste can still be perceived, but wherein the composition is still palatable alone or in combination with other ingredients. The taste masking agent can be present in a sufficient amount to make the composition more palatable relative to the rho kinase inhibitor, although some unpleasant taste may remain, but not enough to prevent a patient from taking the composition. However, the unpleasant taste can be reduced to a level that allows the composition to be used in a placebo-controlled study, such that a patient cannot discern the difference between the same composition with or without the rho kinase inhibitor.

[0032] For bitterness and taste masking, the taster population can include one or more of an average taster, a supertaster and a non-taster. The taster population can substantially include all or uniquely include supertasters, such as to provide an aqueous composition with acceptable palatability that is not affected by the patient applying the composition. The taster can be characterized based on the ability of the taster to detect one or more compounds in a qualitative manner or in a quantitative manner or both. The rho kinase inhibitor of the composition can be used alone, or can be replaced with one or more other compounds alternatively, or used in combination with one or more other compounds to perform a taste test. The taster can be characterized based on the perception of, for example, phenylthiourea (PTC) or 6-n-propylthiouracil or both. The taster can be characterized based on a genetic spectrum limited by one or more taste receptors. The genetic spectrum can be based on one or more alleles of one or more taste receptor genes. One or more taste receptors can include one or more type 2 family taste receptors (T2R). One or more taste receptors can include, for example, the TAS2R38 gene. Allele can include one or more polymorphisms related to taste receptor genes, for example, one or more polymorphisms in TAS2R38 gene. Allele can include one or more haplotypes related to taste receptor genes, for example, one or more polymorphisms in TAS2R38 gene. Polymorphism can include single nucleotide polymorphism (SNP). Three examples of SNP include 145C>G (Pro49Ala), 785C>T (Ala262Val) and 886G>A (Val296Iso). TAS2R38 allele based on SNP can help determine the sensitivity of tasters to bitter taste. PAV (proline, alanine, valine) TAS2R38 haplotype can be used as supertaster and is related to bitter sensitivity. AVI (alanine, valine, isoleucine) TAS2R38 haplotype can be used as no taster variation and is related to bitter insensitivity. PAV homozygous tasters (PAV / PAV) can be classified as supertasters for bitter taste. PAV heterozygous tasters (PAV / AVI) can be classified as (average) tasters for bitter taste. AVI homozygous tasters (AVI / AVI) can be classified as atypical tasters for bitter taste.

[0033] The amount of free, unbound rho kinase inhibitor in the formulation may be less than the taste threshold. In the presence of a pharmaceutical agent that binds a rho kinase inhibitor, the unbound rho kinase inhibitor is typically present in an amount that is no more than about three times the taste threshold. In the range of up to about one times higher than the taste threshold, the taste is generally palatable, but perceptible, even without additional taste masking. In the range of up to about two times higher than the taste threshold, the taste is tolerable and not very palatable. When three times higher than the taste threshold, the taste begins to become offensive without some taste masking. For example, for most people, the taste threshold concentration of fasudil hydrochloride is in the range of 0.1-0.4 mg / mL (the range takes into account "super" tasters and "average" tasters). Therefore, liquid formulations containing fasudil generally do not need to mask the taste at concentrations below this threshold. Exemplary minimum fasudil concentrations for taste-masking liquid formulations include 0.1 mg / mL, 0.2 mg / ml, 0.3 mg / ml, and 0.4 mg / mL. Similarly, the taste threshold of hydroxyfasudil (M3) is in the range of about 0.3 mg / mL to about 0.75 mg / mL, and thus exemplary minimum hydroxyfasudil concentrations for taste-masked liquid hydroxyfasudil formulations are 0.3 mg / ml, 0.4 mg / ml, 0.5 mg / ml, 0.6 mg / mL, and 0.75 mg / mL. The taste threshold of hydroxyfasudil can be, for example, about 0.7 mg / mL to about 0.9 mg / mL. The amount of hydroxyfasudil in the supernatant can be, for example, less than about 3 mg / mL to achieve palatability. When evaluating the potential palatability of a formulation containing an agent that binds a rho kinase inhibitor, the unbound amount (indicative of palatability) should generally be less than three times the taste threshold, about 1 mg / ml for fasudil, and 2.25 mg / ml for hydroxyfasudil.

[0034] Taste masking agents may include bitter masking agents. As used herein, "bitter masking agents" refer to taste masking agents that are configured to directly target or otherwise block the bitter taste of a rho kinase inhibitor, for example, by binding to the rho kinase inhibitor and preventing it from interacting with taste receptors, or binding to bitter receptors in the oral cavity and preventing it from binding to the rho kinase inhibitor. The bitter masking agent may include a single type of molecule or a combination of different molecules that together mask the bitter taste of the rho kinase inhibitor. Different bitter masking agents may utilize the same, similar, or different mechanisms of action. The bitter masking agent may use any suitable mechanism to mask the bitter taste. For example, the bitter masking agent may bind to or otherwise modify the rho kinase inhibitor. The bitter masking agent (e.g., an ion exchange resin, such as a cation exchange resin) may bind to the rho kinase inhibitor. The ion exchange resin may bind less than 50% of the rho kinase inhibitor. The ion exchange resin may bind at least 50%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or about 100% of the rho kinase inhibitor, or any intervening percentage, or any intervening percentage. The more rho kinase inhibitor that is bound to the bitter masking agent, the more effective the taste masking may be. Sufficient bitter masking agent may be added to reduce the concentration of unbound rho kinase inhibitor to a level near or below the taste threshold.

[0035] Certain bitter masking agents can block or otherwise directly inhibit bitter receptors; such bitter masking agents are referred to as "bitter blockers". Examples of bitter blockers include sodium acetate, sodium gluconate, and adenosine 5'-monophosphate. A single type of bitter masking agent may be present in the composition. The composition may include a combination of two or more different types of bitter masking agents. Multiple types of bitter masking agents may act additively or synergistically in their ability to mask the bitter taste of the rho kinase inhibitor. There may be a synergistic effect between the bitter masking agent and one or more other masking agents. Multiple masking agents may act synergistically. Cyclodextrins, particularly β-cyclodextrins, such as hydroxypropyl-β-cyclodextrin and sulfobutyl ether-β-cyclodextrin, represent another class of such bitter masking agents that can complex with rho kinase inhibitors to prevent them from interacting with taste receptors. Ionic polymers (e.g., alginic acid, a linear ionic polymer) are another example of such bitter masking agents. Carbomer is another example of such bitter masking agents.

[0036] Taste masking agents may include one or both of sweeteners and flavoring agents. Any number and any type of sweeteners may be used. Sweeteners may include one or more syrups. Sweeteners may include one or both of sugar and artificial sweeteners. For example, sugar may include sugar alcohols. Sugar may include glucose, fructose, galactose, erythritol, sucrose, lactose, mannose, raffinose or dextrose, or any combination thereof. Sweeteners may include natural sweeteners or artificial sweeteners or both. Natural sweeteners may include, for example, stevioside or another steviol glycoside. Artificial sweeteners may include aspartame, sucralose, acesulfame potassium, saccharin or xylitol, or any salt thereof, or any combination thereof. Sweeteners may include low-calorie or zero-calorie sweeteners; low calories are compared to the calorie content of sucrose. Any number and any type of flavoring agents may be used. Flavoring agents may include natural flavoring agents or artificial flavoring agents or both. Flavoring agent can be fruit or fruit-like flavoring agent, for example, cherry, strawberry, blueberry, banana, orange, lemon, lime, citrus or mango, or any combination thereof. Flavoring agent can be spice or compound with similar spice taste. Other examples of flavoring agent include vanilla, chocolate, cinnamon, menthol, mint, spearmint or peppermint, or any combination thereof. Composition can include coloring agent or the combination of coloring agent. One or more coloring agents can be selected to supplement one or more flavoring agents of composition, and help improve compliance.

[0037] Oral pharmaceutical compositions may include humectants, for example, ammonium alginate, cyclomethicone, glycerol, polydextrose, propylene glycol, sodium hyaluronate, sodium lactate, sorbitol, trehalose, triacetin, triethanolamine or xylitol, or any combination thereof. Compositions may include chelating agents, antioxidants or preservatives, or any combination thereof. Pharmaceutical compositions of the present disclosure may include preservatives. Exemplary preservatives include antioxidants, chelating agents, antimicrobial preservatives, antifungal preservatives, antiprotozoal preservatives, alcohol preservatives, acidic preservatives and other preservatives. Preservatives may be antioxidants. Preservatives may be chelating agents. Exemplary antioxidants include alpha tocopherol, ascorbic acid, ascorbyl palmitate, butylated hydroxyanisole, butylated hydroxytoluene, monothioglycerol, potassium pyrosulfite, propionic acid, propyl gallate, sodium ascorbate, sodium bisulfite, sodium pyrosulfite and sodium sulfite. Exemplary chelating agents include ethylenediaminetetraacetic acid (EDTA) and its salts and hydrates (e.g., sodium edetate, disodium edetate, trisodium edetate, calcium sodium edetate, dipotassium edetate, etc.), citric acid and its salts and hydrates (e.g., citric acid monohydrate), fumaric acid and its salts and hydrates, malic acid and its salts and hydrates, phosphoric acid and its salts and hydrates, and tartaric acid and its salts and hydrates. Exemplary antimicrobial preservatives include benzalkonium chloride, benzethonium chloride, benzyl alcohol, parabens (e.g., methyl paraben, ethyl paraben and propyl paraben and mixtures thereof), sorbic acid, bronopol, cetrimide, cetylpyridinium chloride, chlorhexidine, chlorobutanol, chlorocresol, chloroxylenol, cresol, ethanol, glycerol, hexetidine, imidurea, phenol, phenoxyethanol, phenylethyl alcohol, phenylmercuric nitrate, propylene glycol and thimerosal.

[0038] Oral pharmaceutical compositions may include solid dosage forms or liquid dosage forms, or both. Solid dosage forms may be formulated to target or otherwise promote the absorption of the rho kinase inhibitor at one or more desired locations along the patient's digestive tract. For example, a solid dosage form may be formulated to absorb part or all of the rho kinase inhibitor in the patient's oral cavity or elsewhere in the gastrointestinal tract (such as the intestine). The presence of ion exchange resins alone or in combination with other taste masking agents (e.g., bitter masking agents) may contribute to the palatability of such solid dosage forms. Solid dosage forms may include powders, microparticles, films, tablets or capsules, or any combination thereof. The tablets may include buccal tablets, sublingual tablets, chewable tablets, effervescent tablets, orally disintegrating tablets (ODT), fast dissolving tablets (FDT) or lozenges, or any combination thereof. Powder formulations may be sprays or read to suspension powders.

[0039] Tablets may include a rho kinase inhibitor and an ion exchange resin and one or more excipients, such as one or more of a diluent, a disintegrant, a lubricant, a colorant, a binder, a humectant, an absorbent, a glidant, and a solubilizer. The tablet may be a compressed tablet. The composition of the tablet may be uniform or non-uniform. For example, the tablet may be a multilayer tablet. Capsules may include a rho kinase inhibitor and an ion exchange resin within a shell (e.g., a shell comprising gelatin). Gelatin capsules may include hard gelatin or soft gelatin, or both. Capsules may be considered to be solid dosage forms combined with liquid dosage forms of the present disclosure; the capsules surround a liquid composition of a rho kinase inhibitor and an ion exchange resin. Capsules may include the same or similar excipients as tablets. Tablets and capsules may include powders or microparticles of the present disclosure, or both.

[0040] The powder may include a rho kinase inhibitor and an ion exchange resin. The powder may also include one or more excipients, such as those described for tablets and capsules. The powder may be referred to as a dry powder and still have a moisture content, albeit a low moisture content. The moisture content may vary depending on storage conditions and the specific components present in the powder and their respective hygroscopic or drying properties. The powder may be formulated for direct administration to the oral cavity or for indirect administration via food or beverage or both. The powder may be a finely divided powder. The powder may be a powdered syrup. The powder may be an insufflator formulated for administration using an insufflator. The powder may have any desired size, such as the United States Pharmacopeia (USP) sizes: very coarse (#8), coarse (#20), moderately coarse (#40), fine (#60), and very fine (#80). The powder may be made into microparticles using any suitable method, such as dry granulation or wet granulation. Microparticles may include powders made into larger sized particles. Microparticles may include, for example, effervescent microparticles. Microparticles may include microparticles suitable for filling tablets, capsules, or both. Microparticles may be suitable for mixing with food or beverages.

[0041] Oral pharmaceutical compositions can include isolated particles, or aggregated particles, or both. In a given oral pharmaceutical composition, the particles can be dry or wet. The particles can include powders or microparticles, or both. The particles can have any suitable size, average size, or size distribution. For example, the average length or diameter of the particles can be less than about 0.5 nm, about 0.5 nm to about 500 mm, about 1.0 μm to about 1.0 mm, about 10 μm to about 100 μm, about 25 μm to about 750 μm, about 50 μm to about 500 μm, about 100 μm to about 350 μm, about 60 μm to about 600 μm, about 75 μm to about 150 μm, about 300 μm to about 900 μm, about 400 μm to about 800 μm, about 90 μm to about 1000 μm, about 150 μm to about 1000 μm, about 10 ... The particle size of the particle may be about 90 mm, about 125 μm to about 75 mm, about 250 μm to about 50 mm, about 500 μm to about 25 mm, about 750 μm to about 10 mm, about 1.0 mm to about 5 mm, about 1.0 mm to about 500 mm, about 10 mm to about 350 mm, about 25 mm to about 250 mm, about 50 mm to about 125 mm, about 75 mm to about 100 mm, or more than about 500 mm, or any value therebetween, or any range of values ​​therebetween. Any percentage of the particles may have such a value or range, any percentage of the particles may be below such a value, or any percentage of the particles may be above such a range, or any combination thereof. For example, the percentage can be about 1.0%, about 5.0%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 80%, about 85%, about 90%, about 95%, about 98%, about 99% or about 100%, or any percentage therebetween, or any range therebetween, or any combination thereof. For example, the percentage can be less than 1.0%, about 1.0% to about 100%, about 5% to about 95%, about 10% to about 90%, about 20% to about 80%, about 25% to about 75%, about 30% to about 60%, about 0.5% to about 50%, about 50% to about 100%, about 75% to about 100%, about 90% to about 100%, about 95% to about 100%, or about 99% to about 100%. Such percentages and ranges can also refer to one or more other particle parameters, such as mass, weight, surface area, density, and z value.

[0042] Particle parameters may be measured using any suitable method (e.g., laser diffraction, such as dynamic light scattering). Electrophoretic light scattering may be used. One or more sieves of different pore sizes may be used. A microscope may be used. Particle size may be measured using any suitable metric, method, or device. Particle size may be defined or approximated as an equivalent sphere and a corresponding diameter, where the equivalent sphere shares a property of the actual particle (such as volume or mass or both). Examples of equivalent sphere models include spheres having the same maximum length (d 最大 ), the same minimum length (d 最小 ), same weight (d w ), the same volume (d v ), the same surface area (d s ), the same sieve hole channel (d 筛 ) and the same sedimentation rate (d sed ) sphere. Particle size distribution can be based on one or more of weighted distribution, number weighted distribution, volume weighted distribution and intensity weighted distribution. Average particle size can refer to mean value, median or mode, or any combination thereof. Examples of mean values ​​include number length mean, surface area moment mean and volume moment mean. Particle size distribution can be defined as percentile. For example, percentile can be the product of "X", "a" and "B", where "X" is a selected parameter (such as diameter); "a" is a distribution such as number (n), volume (v) or intensity (i); and "B" is the percentage of particle samples below a given particle size. Examples of percentiles include Dv10, Dv50 and Dv90.

[0043] Particle shape can be characterized by the aspect ratio - width:length. Particle shape can be characterized by the shape of the particle outline. Circularity or sphericity or both can be used to characterize particle shape. Particle symmetry can be measured using kurtosis. The skewness of a particle can be measured. A particle can be defined by its texture (e.g., smoothness or roughness). The zeta potential of a particle can be used to characterize the particle, where the zeta potential is a quantitative measure of the electrostatic or charge repulsion or attraction between particles in a liquid suspension.

[0044] When manufacturing oral pharmaceutical compositions of the present disclosure, grinding can be used to reduce the size of particles, or the size of particles can be increased by granulation, or both methods can be used simultaneously. Particles can be micronized, for example, by jet milling, hammer milling, or fluid energy milling or any combination thereof. Spray drying can use one or more of vibration, kinetic energy, and pressure to micronize particles. One or more of cryogenic, precipitation, ultrasound, and supercritical fluid extraction of emulsions can be used. Cryogenics can include spray freezing into liquid or spray freeze drying, or both.

[0045] One or more granulation methods can be used, such as dry granulation, wet granulation or microwave vacuum granulation, or any combination thereof. Dry granulation can be used. Fluidized bed granulation equipment can include an air handling unit, an exhaust gas turbine, an exhaust gas filter, a processing area, and a product discharge subsystem. The processing area can include one or more of a dryer, a granulator, and a nozzle. The powder can be granulated and then dried with fluidized air. The blended powder can be added to the bowl of a fluidized bed granulator. At the bottom of the bowl, the powder can be fluidized with air, and the weight of the powder can be kept in motion using a sufficiently high speed to support the weight of the powder. A roller compactor can be used during dry granulation. Dry granule coating can be used.

[0046] Wet granulation, such as high shear wet granulation, can be used. One or more of oscillating, cord-like, capillary and droplet mobile flow states can be generated and monitored. The mobile flow state can be adjusted by controlling the liquid content in the microparticle pores during formation. A stable liquid film can be produced, for example, using a high viscosity granulation solution. A high shear granulator can be used to mix powders, or the powders can be granulated, or both can be performed. In fluidized bed granulation, one or more granulation modes can be used, such as top spray, bottom spray and tangential spray modes. Any suitable parameters can be set or changed, such as one or more of spray rate, droplet size, atomizing spray pressure, inlet air temperature, dew point and fluidizing air volume. Parameters can include one or more of the following: fluidizing air flow rate, inlet air temperature, humidity, granulation solution flow rate, binder solution flow rate, binder solution atomization pressure, binder solution volume, nozzle size and nozzle height. The airflow volume and drying rate can be adjusted to achieve the target particle size. Adhesive, liquid or both can be used to form microparticles. The liquid may be a volatile solvent that may be removed during drying. Examples of solvents include one or more of: water, ethanol, and isopropanol.

[0047] Oral pharmaceutical compositions may include a coating. The coating may be located on the rho kinase inhibitor and the ion exchange resin, such as on a complex of the rho kinase inhibitor and the ion exchange resin. The coating may cover less than about 10%, about 10% to 100%, about 15% to about 99%, about 20% to about 95%, about 25% to about 90%, about 30% to about 85%, about 40% to about 75%, or about 50% to about 60%, or any intermediate percentage or percentage range of the rho kinase inhibitor and the ion exchange resin. The coating may include an enteric coating or a controlled release coating, or both. The coating may include a taste masking agent, such as a bitter masking agent, a sweetener or a flavoring agent, or any combination thereof. On a weight / weight (w / w) basis relative to the ion exchange resin bound to the rho kinase inhibitor, the coating can include less than about 10%, about 10% to 100%, about 15% to about 99%, about 20% to about 95%, about 25% to about 90%, about 30% to about 85%, about 40% to about 75%, or about 50% to about 60%, or any intervening percentage or range of percentages of rho kinase inhibitor and ion exchange resin.

[0048] The oral pharmaceutical composition may include a plurality of particles comprising a rho kinase inhibitor and an ion exchange resin. The plurality of particles may include, for example, a powder or microparticles, or both. The powder or microparticles or both may be provided in the form of a spray for food or beverage. The oral pharmaceutical composition may include a coating covering the plurality of particles. The particles may be coated individually, or in large quantities together, or in both forms. The coating may include a colorant, a pattern, a symbol or text, or any combination thereof. Oral pharmaceutical compositions can include one or more coating agents such as acetyl tributyl citrate, acetyl triethyl citrate, calcium carbonate, sodium carboxymethyl cellulose, carnauba wax, cellulose acetate, cellulose acetate phthalate, cetyl alcohol, chitosan, ethyl cellulose, fructose, gelatin, glycerin, glyceryl behenate, glyceryl palmitostearate, hydroxyethyl cellulose, hydroxyethyl methyl cellulose, hydroxypropyl cellulose, hypromellose, hypromellose phthalate, isomalt, latex particles, liquid glucose, maltitol, maltodextrin, methyl cellulose, microcrystalline wax, paraffin, poloxamer, polydextrose, polyethylene glycol, polyvinyl acetate, polyvinyl acetate phthalate, polyvinyl alcohol, potassium chloride, povidone, shellac, stearic acid, sucrose, tributyl citrate, triethyl citrate, vanillin, white wax, xylitol, yellow wax or zein, or any combination thereof.

[0049] Fluidized bed systems and methods can be used to coat particles or microparticles or both. Examples of coating systems and methods, fluidized beds or other forms include water-based coatings, hot melt coatings, supercritical fluid coatings, steam coatings, electrostatic coatings, rotary / centrifugal coatings, magnetic assisted impact coatings (MAIC), mixers, theta composers, mechanical fusion, spheroidization, chemical vapor deposition (CVD), and atomic layer deposition (ALD) systems and methods. Wet granule coatings can be used. Any suitable coating material can be used, such as one or more polymers. The polymer can include one or more of the following: homopolymers, copolymers, block copolymers, random copolymers, gradient copolymers, graft copolymers, statistical copolymers, alternating copolymers, stereoblock copolymers, and crosslinked polymers.

[0050] Any suitable excipient or combination of excipients can be used in the oral pharmaceutical composition. Any suitable diluent or combination of diluents can be used, such as ammonium alginate, calcium carbonate, calcium phosphate, calcium sulfate, cellulose, cellulose acetate, compressible sugar, icing sugar, dextrates, dextrin, dextrose, erythritol, ethyl cellulose, fructose, fumaric acid, stearyl palmitin, hydrogenated vegetable oil, isomalt, kaolin, lactitol, lactose, magnesium carbonate, magnesium oxide, maltodextrin, maltose, mannitol, triglyceride, microcrystalline cellulose, polydextrose, polymethacrylate, simethicone, sodium alginate, sodium chloride, sorbitol, starch, sucrose, sugar spheres, sulfobutyl ether beta-cyclodextrin, talc, tragacanth, trehalose or xylitol, or any combination thereof. Any suitable disintegrant or combination of disintegrants may be used, such as alginic acid, calcium alginate, calcium carboxymethylcellulose, sodium carboxymethylcellulose, cellulose, chitosan, colloidal silica, cross-linked sodium carboxymethylcellulose, crospovidone, sodium docusate, guar gum, hydroxypropyl cellulose, magnesium aluminum silicate, methylcellulose, microcrystalline cellulose, polacrilin potassium, povidone, sodium alginate, sodium starch glycolate or starch, or any combination thereof. Any suitable lubricant or combination of lubricants may be used, such as calcium stearate, glyceryl monostearate, glyceryl behenate, glyceryl palmitostearate, hydrogenated castor oil, hydrogenated vegetable oil, light mineral oil, magnesium stearate, triglycerides, mineral oil, myristic acid, palmitic acid, poloxamer, polyethylene glycol, potassium benzoate, sodium benzoate, sodium chloride, sodium lauryl sulfate, sodium stearyl fumarate, stearic acid, talc or zinc stearate, or any combination thereof.

[0051] Any suitable binder or combination of binders can be used, for example, acacia, agar, alginic acid, carbomer, sodium carboxymethylcellulose, carrageenan, cellulose acetate phthalate, carob bean gum, chitosan, powdered sugar, copovidone, cottonseed oil, dextrates, dextrin, dextrose, ethylcellulose, gelatin, glyceryl behenate, guar gum, hydrogenated vegetable oils, hydroxyethylcellulose, hydroxyethyl methylcellulose, hydroxypropyl cellulose, hydroxypropyl starch, hydroxypropyl methylcellulose, inulin, lactose, liquid glucose, magnesium aluminum silicate, maltodextrin, maltose, methylcellulose, microcrystalline cellulose, poloxamer, polycarbophil, polydextrose, polyethylene oxide, polymethacrylate, povidone, sodium alginate, starch, stearic acid, sucrose, sunflower oil or zein, or any combination thereof. Any suitable glidant or combination of glidants can be used, such as tricalcium phosphate, calcium silicate, powdered cellulose, colloidal silica, magnesium silicate, magnesium trisilicate, silicon dioxide, starch or talc, or any combination thereof. Any suitable solubilizer or combination of solubilizers can be used, such as benzalkonium chloride, benzethonium chloride, benzyl alcohol, benzyl benzoate, cetylpyridinium chloride, cyclodextrin, glyceryl monostearate, lecithin, meglumine, poloxamer, polyethylene alkyl ether, polyoxyethylene alkyl ether, polyoxyethylene castor oil, polyoxyethylene sorbitan fatty acid ester, polyoxyethylene stearate, povidone, 2-pyrrolidone, sodium bicarbonate, sorbitan ester, stearic acid or sulfobutyl ether beta-cyclodextrin, or any combination thereof.

[0052] Oral pharmaceutical compositions may include one or more suitable controlled release agents, for example, acetyl tributyl citrate, acetyl triethyl citrate, aliphatic polyesters, bentonite biodegradable polymers, carbomer, carrageenan, cellulose acetate, cellulose acetate phthalate, carob gum, cetyl alcohol, cetyl ester wax, chitosan, dibutyl sebacate, ethyl cellulose, glyceryl monostearate, glyceryl behenate, glyceryl monooleate, glyceryl monostearate, glyceryl palmitostearate, guar gum, hydrogenated vegetable oils, glyceryl stearate ... vegetable oil, hydroxypropyl cellulose, hydroxypropyl methylcellulose acetate succinate, isopropyl palmitate, magnesium aluminum silicate, magnesium oxide, methylcellulose, microcrystalline wax, paraffin, peanut oil, polacrilin potassium, polycarbophil, polyethylene oxide, polymethacrylate, potassium chloride, povidone, sesame oil, sodium bicarbonate, sodium chloride, stearic acid, stearyl alcohol, talc, tributyl citrate, triethyl citrate, ethyl carbamate hydrogel, white wax, xanthan gum, yellow wax, polyvinyl acetate or zein, or any combination thereof.

[0053] Oral pharmaceutical compositions may include aqueous compositions. The aqueous compositions may include solutions, suspensions, emulsions, gels or colloids, or any combination thereof. The aqueous compositions may include single phase or multiple phases. The aqueous compositions may be elixirs. The aqueous compositions may be syrups. Water may be the only solvent present in the aqueous compositions. One or more additional solvents may be present in the aqueous compositions. Additional solvents may include, for example, ethanol, glycerol, propylene glycol or polyethylene glycol, or any combination thereof. One or more components of the aqueous compositions may be in solution. The aqueous compositions may be dried, lyophilized, concentrated, emulsified, blended or encapsulated, or any combination thereof, to form solid dosage forms of the present disclosure.

[0054] One or more components of the same aqueous solution can be suspended.After mixing, shaking, vortex, sonication or other stirring, the component in the suspension can keep less than about 10 seconds, about 10 seconds to about 10 years, about 30 seconds to about 5 years, about 1.0 minutes to about 2.5 years, about 2.0 minutes to about 1.5 years, about 5.0 minutes to about 1.0 years, about 10 minutes to about 8 months, about 20 minutes to about 6 months, about 30 minutes to about 3 months, about 1.0 hours to about 1.0 months, about 3.0 hours to about 30 days, about 6.0 hours to about 3 weeks, about 12 hours to about 2.0 weeks, about 1.0 days to about 1.0 weeks, about 3 days or more than 10.0 years, or any period therebetween, or any scope therebetween.Can prepare, store or use aqueous composition at any suitable temperature. For example, the temperature can be below about -20°C, about -20°C to about 100°C, about -10°C to about 75°C, about 0°C to about 60°C, about 5°C to about 50°C, about 10°C to about 40°C, about 15°C to about 30°C, about 20°C to about 25°C, or about ambient temperature, or any temperature therebetween, or any range therebetween. The composition can be stored at controlled room temperature, for example, in the range of 20°C to 30°C. The aqueous composition can be lyophilized and later reconstituted. The aqueous composition can be concentrated and later diluted.

[0055] Oral pharmaceutical compositions may include one or more suspending agents. Suspending agents are agents that help suspend one or more components of a composition when the composition is formulated into an aqueous composition. Suspending agents may also have one or more other functions. Suspending agents may include, for example, viscosity modifiers or dispersants. Viscosity modifiers may include, for example, thickeners (thickeners) or diluents or both. Suspending agents may include cellulose or a derivative thereof, for example, a cellulose ether or a cellulose ester or both. One or more wetting agents may be used. Cellulose ethers may include one or more cellulose ethers. Cellulose ethers may include, for example, methylcellulose (MC), ethylcellulose (EC), hydroxyethylcellulose (HEC), hydroxypropylcellulose (HPC), hydroxyethylmethylcellulose (HEMC), hydroxypropylmethylcellulose (HPMC), carboxymethylcellulose (CMC) or sodium carboxymethylcellulose (NaCMC), or any combination thereof. Cellulose esters may include one or more cellulose esters. Cellulose esters may include, for example, esters of one or more acids including about one to about six carbons. Cellulose esters may include, for example, cellulose acetate, cellulose propionate, cellulose butyrate, cellulose nitrate, cellulose phosphate or cellulose sulfate, or any combination thereof.

[0056] The suspending agent may include one or more non-cellulosic polysaccharides. For example, the non-cellulosic polysaccharide may include one or more gums. The non-cellulosic polysaccharide may include pentoses, hexoses or both. The non-cellulosic polysaccharide may include one or more types of monosaccharides. The non-cellulosic polysaccharide may include two or more of glucose, mannose and glucuronic acid. The non-cellulosic polysaccharide may include repeating subunits, the repeating subunits including two glucose residues, two mannose residues and one glucuronic acid residue. The non-cellulosic polysaccharide may include one or more gums. The gum may include synthetic gums or natural gums or both. The gum may include guar gum, ghatti gum, karayagum, khaya gum, tragacanth gum, carrageenan, acacia gum, albizi gum, almond gum, bhara gum, carob gum, cashew gum, benjamin gum, olibanum gum, gellan gum, locust bean gum, pullulan gum, phosphomannan gum, scleroglucan gum, tamarind gum, xanthan gum, alginate, starch, dextrin or pectin, or any combination thereof. The suspending agent may include one or more pyrrolidone-containing polymers. The polymer containing pyrrolidone can include a cross-linked polymer containing pyrrolidone. The polymer containing pyrrolidone can include povidone, copolyvidone or crospovidone, or any combination thereof. The suspending agent can include one or more of bentonite, calcium stearate, carbomer, colloidal silica, gelatin, kaolin, magnesium aluminum silicate, monoglyceride, diglyceride, triglyceride, polycarbophil, polyethylene glycol or oil, or any combination thereof.

[0057] The composition may include any number of different suspending agents. For example, the composition may include one, two, three, four, five, six or more different suspending agents. The composition may include a first suspending agent and a second suspending agent. The first suspending agent may include, for example, a cellulose ether, and the second suspending agent may include, for example, a non-cellulose polysaccharide. The composition may include any suitable amount of the first suspending agent and the second suspending agent. The composition may include any suitable ratio of the first suspending agent to the second suspending agent, for example, the weight ratio of the first suspending agent to the second suspending agent may be about 1:100 to about 1:1, about 1:50 to about 1:25, about 1:25 to about 1:10, about 1:10 to about 1:5, about 1:5 to about 1:2.5, about 100:1 to about 1:1, about 50:1 to about 25:1, about 25:1 to about 10:1, about 5:1 to about 2.5:1, about 1.5:1 to about 3:1, about 2.0:1 to about 2.7:1 or about 2.5:1, or any ratio in between, or any range in between.

[0058] Aqueous compositions can be buffered to resist or minimize pH changes. For example, aqueous compositions or other compositions can include buffers. Exemplary buffers include citrate buffer, acetate buffer, phosphate buffer, ammonium chloride, calcium carbonate, calcium chloride, calcium citrate, calcium glucuronate, calcium glucoheptonic acid, calcium gluconate, D-gluconic acid, calcium glycerophosphate, calcium lactate, propionic acid, calcium levulinate, valeric acid, dibasic calcium phosphate, phosphoric acid, tribasic calcium phosphate, calcium hydroxide phosphate, potassium acetate, potassium chloride, potassium gluconate, potassium mixture, dibasic potassium phosphate, monobasic potassium phosphate, potassium phosphate mixture, sodium acetate, sodium bicarbonate, sodium chloride, sodium citrate, sodium lactate, dibasic sodium phosphate, monobasic sodium phosphate, sodium phosphate mixture, tromethamine, magnesium hydroxide, aluminum hydroxide, alginic acid, pyrogen-free water, isotonic saline, Ringer's solution or ethanol, or any combination thereof. The pH of the aqueous composition can be less than about 4.0, greater than about 10.0, about 4.0 to about 10.0, about 5.0 to about 8.0, about 5.5 to about 7.5, about 6.0 to about 7.0, about 6.2 to about 6.8, or about 6.3 to about 6.5, or any value therebetween, or any range therebetween. The pH of the aqueous composition can affect the bitterness of the rho kinase inhibitor, and in turn affect the taste threshold concentration. The pH can be slightly acidic to help improve palatability.

[0059] The aqueous composition can be formulated into an oil-in-water emulsion, a water-in-oil emulsion, or both. One or more components of the aqueous composition can be in the aqueous phase of the emulsion. One or more components of the same aqueous solution can be in the oil phase of the emulsion. The aqueous composition can include an emulsifier. The emulsifier can include one or more suspending agents. Emulsifiers can include, for example, anionic emulsifying wax, calcium stearate, carbomer, cetearyl alcohol, cetyl alcohol, cholesterol, diethanolamine, ethylene glycol palmitate, glyceryl monostearate, glyceryl monooleate, laponite, lanolin, lauric acid, lecithin, linoleic acid, triglycerides, mineral oil, sodium dihydrogen phosphate, monoethanolamine, myristic acid, nonionic emulsifying wax, octyldodecanol, oleic acid, oleyl alcohol, palmitic acid, polycarbophil, polyoxyethylene alkyl ether, polyoxyethylene castor oil derivatives, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene stearate, saponin, self-emulsifying glyceryl monostearate, sodium borate, sodium citrate dihydrate, sodium lauryl sulfate, sorbitan esters, stearic acid or triethanolamine, or any combination thereof.

[0060] The aqueous composition can be formulated into a gel. One or more gelling agents can be used, for example, aluminum stearate, calcium silicate, carbomer, sodium carboxymethylcellulose, carrageenan, chitosan, colloidal silica, gelatin, glyceryl monooleate, stearyl palmitate, guar gum, hydroxyethyl cellulose, microcrystalline cellulose, pectin, polyethylene alkyl ether, polyethylene glycol, polyethylene oxide, polymethacrylate, propylene carbonate, sodium ascorbate, sodium alginate, sorbitol, ethyl carbamate or zinc acetate, or any combination thereof. The gel can have any desired viscosity. Gel or other compositions described herein can be thixotropic.

[0061] The rho kinase inhibitor may be present in a concentration that allows for the administration of a reasonable volume of the aqueous composition per dose. For example, the rho kinase inhibitor may be present in an amount of about 0.1% w / v to about 10% w / v of the aqueous composition, about 0.25% w / v to about 4.0% w / v, about 0.33% w / v to about 3.0% w / v, about 0.5% w / v to about 5.0% w / v, about 1.0% w / v to about 2.5% w / v, about 1.0% w / v to about 4.9% w / v, about 1.0% w / v to about 3.0% w / v, about 1.2% w / v to about 1.8% w / v, about 1.5% w / v to about 2.0% w / v, or any intervening percentage, or any intervening range. The taste threshold concentration may also correspond to one or more of these percentages or ranges. The reasonable volume of a single dose can be less than about 1.0mL, about 1.0mL to about 1.0L, about 2.5mL to about 500mL, about 4.0mL to about 8mL, about 4.5mL to about 6mL, about 5.0mL to about 250mL, about 7.5mL to about 100mL, about 10mL to about 50mL, about 15mL to about 30mL or greater than about 1.0L, or any volume in between, or any volume range in between. The administration volume range can be, for example, 0.5ml to 20mL or 1mL to 10mL or 3mL to 6mL. The composition can be provided in the form of a concentrate, and then diluted before use.

[0062] The taste threshold concentration is a concentration above which, typically, a patient can perceive the bitter taste of a rho kinase inhibitor. The taste threshold concentration may be of great significance for at least two reasons. First, it may identify a concentration above which taste masking is desirable. Thus, liquid formulations requiring taste masking will contain active ingredients at concentrations above the taste threshold. Second, in cases where a formulation contains a taste masking agent that is bound or complexed to the active ingredient, the taste threshold becomes a target for assessing the amount of "free" active ingredient. Taste masking may be most effective when the supernatant / unbound fraction contains active ingredients at concentrations close to or below the taste threshold.

[0063] The amount of free unbound rho kinase inhibitor in the formulation may be less than the taste threshold. The unbound rho kinase inhibitor may be present in an amount not exceeding twice the taste threshold. For example, for most people, the taste threshold concentration of fasudil hydrochloride is in the range of 0.3-0.4 mg / ml. Therefore, the minimum total (bound and unbound) concentration of a liquid formulation containing fasudil for taste masking may be higher than 0.3-0.4 mg / ml, and an effective taste masking formulation may have no more than about 1 mg / ml of unbound fasudil.

[0064] The threshold concentration can be less than about 0.01 mg / mL, about 0.01 mg / mL to about 10 mg / mL, about 0.5 mg / mL to about 5.0 mg / mL, about 1.0 mg / mL to about 3.0 mg / mL, greater than about 10 mg / mL, about 0.01 mg / mL to about 100 mg / mL, about 0.1 mg / mL to about 75 mg / mL, about 0.2 mg / mL to about 0.5 mg / mL, about 0.3 mg / mL to about 0.4 mg / mL, about 0.25 mg / mL to about 0.35 mg / mL, about 0.5 mg / mL to about 50 mg / mL, about 1.0 mg / mL to about 25 mg / mL, about 2.0 mg / mL to about 20 mg / mL, about 2.5 mg / mL to about 15 mg / mL, or greater than about 100 mg / mL, or any concentration therein, or any range in between. These ranges can be converted into concentrations corresponding to the weight percentage of the solid dosage form. The rho kinase inhibitor can be present in any corresponding concentration or range. The taste threshold concentration may be affected and adjusted based on one or more parameters of the taste masking composition. For example, the taste threshold concentration may be affected or adjusted based on pH, the taste of one or more other compounds present in the taste masking composition, temperature, or viscosity, or any combination thereof.

[0065] Each of the one or more suspending agents can be present in the composition in any suitable amount. The suspending agent can be present in an amount, for example, less than about 0.1% w / v, about 0.1% w / v to about 50% w / v, about 0.25% w / v to about 25% w / v, about 1.0% w / v to about 20% w / v, about 1.5% w / v to about 15% w / v, about 2.0% w / v to about 10% w / v, about 2.5% w / v to about 7.5% w / v, about 3.5% w / v to about 6.0% w / v, about 4.0% w / v to about 5.0% w / v, or greater than about 25% w / v of the aqueous composition, or any intervening percentage, or any intervening percentage range. For example, the first suspending agent may comprise about 0.5% w / v to about 2.0% w / v of the aqueous composition and the second suspending agent may comprise about 0.1% w / v to about 1.0% w / v of the aqueous composition, or vice versa.

[0066] Oral pharmaceutical compositions can have any desired viscosity.For example, the viscosity of aqueous compositions can be less than about 1.0 cSt, about 1.0 cSt to about 1,000 cSt, about 5.0 cSt to about 500 cSt, about 10 cSt to about 400 cSt, about 25 cSt to about 300 cSt, about 40 cSt to about 250 cSt, about 50 cSt to about 200 cSt, about 50 cSt to about 2,500 cSt, about 60 cSt to about 180 cSt, about 75 cSt to about 150 cSt, about 100 cSt, about 500 cSt to about 5,000 cSt, about 1,000 cSt to about 3,500 cST, greater than about 1,000 cST, greater than about 5,000 cST or any viscosity in between, or any scope in between.Selected viscosity value or scope can be optionally realized by the presence of viscosity modifier.Specific viscosity can be selected to help improve compliance. Aqueous compositions can be formulated according to the International Dysphagia Diet Standardization Initiative (IDDSI), with a beverage consistency scale of "0" for thin, "1" for slightly thick, "2" for slightly thick, "3" for medium consistency, or "4" for very thick, as determined by the IDDSI flow test, all of which are incorporated herein in their entirety. The IDDSI Framework and Detailed Level Definitions (July 2019) are incorporated herein by reference in their entirety. Suspensions for dysphagia populations can, for example, be in the range of 2 on the IDDSI scale.

[0067] The oral pharmaceutical composition of the present disclosure can be packaged in any suitable form. For example, the composition can be packaged in a bottle or other liquid container in a ready-to-use form. An optional cup or other volume dispenser can be supplied with the bottle. The volume of the cup can be related to the predetermined volume dose of the composition. The cup can be optionally marked with a scale to allow volume measurement. The cup can include one or more scales or other markings indicating one or more volume doses. The composition can be packaged as a dry concentrate, a liquid concentrate, or both. The composition can be packaged in a separate mixture so that one or more components are separated from one or more other components in two or more compartments of the package. The non-liquid or non-aqueous dosage form of the composition can reside in a single chamber or a separate chamber of the package. Pouches, sticks, capsules, or blister packages or any combination thereof can be used, for example, wherein each pouch, stick, capsule, or blister unit of the package contains a dose of powder, granules, or sprays or any combination thereof, for example, for application to food or beverage or both.

[0068] Thus, a composition is provided which may include at least a bitter rho kinase inhibitor and an ion exchange resin. Once bound to the ion exchange resin, the complex may be used directly as a medicament, or it may be used as a building block to be included in other formulations. In other methods, it may be, for example, pressed into tablets, packaged, powdered for the preparation of suspensions. Because the present invention relates to pharmaceutical formulations, it does not relate to fasudil or any other rho kinase inhibitor bound to an ion exchange resin on a chromatographic column. The resin in such a column does not meet good manufacturing process standards and is not suitable for human consumption, let alone pharmaceutical use. Therefore, the formulation according to the present invention explicitly does not include a chromatographic column. Formulations such as dry powders, microparticles, beads, etc. can be conveniently divided into unit doses. Such unit doses typically contain between 20 mg and 180 mg of fasudil hydrochloride hemihydrate and a cation exchange resin in a ratio (drug: resin) of about 1:2 to about 1:5, about 1:2.75 to about 1:3.3, about 1:2.5 to about 1:4.5 or about 1:3 (w / w). Other unit doses will contain an appropriate amount of fasudil for the dose sought and a corresponding amount of resin. Exemplary unit doses may contain 20 mg, 30 mg, 40 mg, 60 mg, 80 mg, 120 mg or 180 mg of fasudil hydrochloride hemihydrate.

[0069] The taste-masking composition can be formulated so that the composition is easily administered to a subject with dysphagia. Dysphagia is characterized by difficulty swallowing. Dysphagia may be associated with difficulty moving food or liquids from the mouth to the throat or through the esophagus. Dysphagia may have any number of different causes. For example, dysphagia may be caused by a neurodegenerative disease such as Alzheimer's disease, vascular dementia, amyotrophic lateral sclerosis (ALS), motor neuron disease (including amyotrophic lateral sclerosis (ALS), progressive bulbar palsy (PBP), pseudobulbar palsy, progressive muscular atrophy (PMA), primary lateral sclerosis (PLS), spinal muscular atrophy (SMA) and mononuclear muscular atrophy (MMA) as well as some rarer variants similar to ALS), Parkinson's disease, Huntington's disease, multiple sclerosis, progressive supranuclear palsy (PSP) or corticobasal syndrome (CBS), or any combination thereof; or a condition affecting the nervous system, such as a stroke or head injury; cancer, such as oral cancer or esophageal cancer; or gastroesophageal reflux disease (GORD), in which stomach acid leaks back into the esophagus. Signs and symptoms associated with dysphagia may include, for example, one or more of pain when swallowing, inability to swallow, sensation of food stuck in the throat or chest or behind the sternum (chest plate), drooling, hoarseness, food regurgitation (regurgitation), frequent heartburn, food or stomach acid backing up into the throat, or coughing or gagging when swallowing. Dysphagia-friendly formulations may be suitable for subjects of any age. Such formulations may be used for the elderly, but are also helpful when administered to pediatric or adult patients who do not necessarily suffer from dysphagia, based on body weight, renal function, body surface area, or any number of potential variables.

[0070] The composition can be formulated such that the rho kinase inhibitor is present in an amount sufficient to treat a neurodegenerative disease. The neurodegenerative disease can include, for example, Alzheimer's disease, vascular dementia, amyotrophic lateral sclerosis (ALS), Parkinson's disease, Huntington's disease, multiple sclerosis, progressive supranuclear palsy (PSP), or corticobasal syndrome (CBS), or any combination thereof.

[0071] Provided is a method for treating a neurodegenerative disease, the method comprising administering a composition of the present disclosure to a patient in an amount sufficient to treat the neurodegenerative disease. For example, the amount of the rho kinase inhibitor per dose can be less than about 0.5 mg, about 0.5 mg to about 250 mg, about 5.0 mg to about 225 mg, about 10 mg to about 200 mg, about 20 mg to about 180 mg, about 25 mg to about 170 mg, about 30 mg to about 160 mg, about 40 mg to about 150 mg, about 50 mg to about 140 mg, about 60 mg to about 120 mg, about 75 mg to about 100 mg or more than 250 mg, or any amount therebetween, or any range therebetween. These amounts can refer to a rho kinase inhibitor, a pharmaceutically acceptable salt thereof, a hydrate thereof, a prodrug thereof, a substituted derivative thereof, or a metabolite thereof, or any combination thereof. These doses can be delivered in a single dosage form or in multiple dosage forms. Multiple dosage units (e.g., tablets or capsules) can be administered simultaneously, or sequentially in a given time period (e.g., 24 hours a day), or in both ways to achieve the target dose. Table A describes some examples of daily doses for various therapeutic goals. Doses outside these ranges or overlapping therewith can also be used. The dose can be adjusted based on the weight, health status, and other factors of a particular patient or a group of patients. In an immediate release formulation administered 2-3 times a day, the daily dose of fasudil can be 180 to 360 mg. Therefore, each individual dose will contain 60-180 mg of fasudil, such as 60 mg, 90 mg, 120 mg, or 180 mg.

[0072] Fasudil hydrochloride hemihydrate may be replaced by a molar equivalent of another salt, hydrate, prodrug or active metabolite of fasudil or other rho kinase inhibitors. Administration may be performed once a day, twice a day, three times a day, four times a day, once every two days, once every three days, once a week, once every other week, once a month, at a lower frequency, at a higher frequency, or at any frequency in between or within any frequency range in between. For example, in an immediate release formulation administered 2 to 3 times a day, the daily dose of fasudil may be at least 70 mg, but is typically 180 mg to 360 mg. Each individual dose may contain 60-180 mg of fasudil, for example, 60 mg, 90 mg, 120 mg or 180 mg. Due to low delivery efficiency, such as incomplete release, extended-release formulations will generally contain more active substances in proportion. Thus, for example, a sustained-release formulation intended to deliver a full day's dose may contain an additional 10%-20% of fasudil. Examples of daily dose ranges are shown in Table B. The daily dosage range may be wider than that shown in Table B; the range may be shifted to lower or higher dosages. 180 mg / day is not an upper limit, for example, the dosage range may be 240 mg / day or higher.

[0073] Table B

[0074]

[0075]

[0076] The dosage can be modified and customized for specific patient conditions. For example, the dosage can be modified for patients with renal impairment. The fasudil dosage for patients with mild to moderate renal impairment can be reduced to about 5.0 to about 25 mg per day to about 2.5 mg to about 15 mg per day. A single dose of fasudil can be used. The dosage can be reduced for patients with serum creatinine (SCr)>2 and / or SCr increased by>1.5 times relative to baseline and / or eGFR decreased by>25% relative to baseline. Liver health and metabolic enzyme alleles can be considered when dosing. For example, the dosage can be modified based on whether the patient is a fast metabolizer or a slow metabolizer of fasudil or other rho kinase inhibitors. When using a creatinine-based renal function assessment, the patient's body size can be taken into consideration. Volume / time (ml / min) drug clearance units can be used, and volume / time / standard size (ml / min / 1.73m 2 ) units of estimated GFR for chronic kidney disease. For smaller patients, the dosage can be adjusted downward (e.g., to about 2.5 mg to about 15 mg per day), while for obese patients, the dosage can be adjusted upward (e.g., up to 30 mg per day). Smaller males can be about 160 pounds or less. Smaller female patients can weigh about 130 pounds or less. Patients with a body mass index (BMI) of 30 or more are considered obese.

[0077] Lower doses may be administered to elderly patients at the beginning and gradually increased to the recommended dose after a few days or weeks. Lower doses may be administered to elderly patients over the duration of treatment. Elderly populations may include "young elderly" who may be about 65 to about 74 years old, "old elderly" who may be about 75 to about 84 years old, and "frail elderly" who may be 85 years old and above. For example, a starting dose of 10 mg per day may be administered for two weeks, followed by 20 mg per day for 4 weeks, and then 25 mg per day. Titration may be performed, for example, up to 30 mg per day. The method of administering the composition may last for any suitable duration, for example, at least one day, up to 30 days, up to 60 days, or up to 90 days, at least six months, or more than 90 days. The duration of treatment may depend on the patient's condition and the response to treatment. A method may further include diagnosing a patient's neurodegenerative disease before the composition is administered to the patient. Treatment of neurodegenerative diseases may include improving the symptoms of neurodegenerative diseases. Administration may include self-administration. The method may include tracking compliance with administration. A method can further include diagnosing the patient for a non-neurodegenerative disease prior to administering the composition to the patient.

[0078] The compositions or methods of the present disclosure or both can combine one or more rho kinase inhibitors (e.g., fasudil) with other compounds for treating dementia or other dementia symptoms. They can be administered in combination, in a single dosage form, in a separate dosage form, by the same route of administration, by different routes of administration, with a common dosing regimen, or with an independent dosing regimen or any combination thereof. The composition can include, for example, fasudil and one or more active pharmaceutical ingredients (API) suitable for treating cortical dementia, for example, cholinesterase inhibitors and NMDA receptor antagonists. The cholinesterase inhibitor can be selected from one or more of donepezil, rivastigmine, and galantamine. Exemplary dosages of cholinesterase inhibitors can include about 3.0 mg to about 25 mg per day, or about 6.0 mg to about 12 mg per day. The NMDA receptor antagonist can be memantine. For example, memantine can be administered at a dosage of about 5.0 to about 28 mg per day or about 15 mg to about 20 mg per day. The co-administered API can be, for example, a combination of donepezil and memantine, with memantine at a dose of about 28 mg and donepezil at a dose of about 10 mg. The combination of fasudil and one or more cholinesterase inhibitors can be administered to wandering patients with proteinopathy-related cortical dementia. The combination of fasudil and a cholinesterase inhibitor can be administered to wandering patients with mixed dementia. For wandering patients who only suffer from vascular cortical dementia, the administration of the combination of fasudil and a cholinesterase inhibitor can be excluded. Dextromethorphan hydrobromide is another NMDA receptor antagonist that also has activity like a sigma-1 receptor agonist. The product Nudexta is marketed in combination with quinidine sulfate (a CYP450 2D6 inhibitor) for the treatment of pseudobulbar mood that occurs in various forms of dementia. Such APIs and drugs can be administered in combination with rho kinase inhibitors such as fasudil. A patient treated with a composition described herein can be treated for depression, for example, a patient being treated with an antidepressant such as citalopram or escitalopram.

[0079] The present disclosure provides a method, which includes applying the compositions of the present disclosure to the patient in an amount sufficient to treat general diseases or improve the symptoms of neurodegenerative diseases.Diseases can include, for example, dementia, Huntington's disease, autism spectrum disorder, Down syndrome, Alzheimer's disease, Lewy body dementia, frontotemporal dementia, chronic head injury, normal pressure hydrocephalus, Creutzfeldt-Jakob disease, amyotrophic lateral sclerosis, Parkinson's disease, multiple system atrophy (MSA), amyotrophic lateral sclerosis (ALS) and other motor neuron diseases.Other motor neurons and diseases include, for example, X-linked spinal bulbar muscular atrophy (Kennedy's disease), adult Tay-Sach's disease, spinal muscular atrophy, multifocal motor neuropathy with conduction block, primary lateral sclerosis and familial spastic paraplegia, or any combination thereof.Dementia related to cerebrovascular accident (CVA or stroke) can be referred to as vascular dementia.

[0080] An example of a symptom is wandering. Wandering can include behaviors such as excessive movement and pacing. Patients can be assessed by assessing physical parameters, psychological parameters, or both. Assessment can be performed by language neurological tests, such as written neurological tests or verbal neurological tests or both. Assessment can be performed by observing the patient's physical behavior or psychological behavior or both. Assessment can be performed by imaging, such as brain computer-assisted tomography (CAT), brain magnetic resonance imaging (MRI), brain diffusion tensor imaging (DTI), or brain positron emission tomography (PET), or any combination thereof. Imaging can assess any suitable feature, such as blood flow, brain size, brain morphology, brain tissue, or physical features of the brain, or any combination thereof relative to the whole brain or its parts. Physical features can include, for example, plaques, tangles, bodies, or inclusions, or any combination thereof. Exemplary relevant brain parts include ventricles, hippocampus, frontal operculum, precentral gyrus, midbrain, pons, and superior cerebellar peduncles, complete white matter bundles, oblique bundles, superior longitudinal bundles, superior cerebellar peduncles, or substantia nigra, or any combination thereof. One or more biomarkers can be evaluated, for example, from patient urine, patient blood or unclosed cerebrospinal fluid or any combination thereof. Biomarkers can include, for example, nucleic acids, proteins, polysaccharides, lipids, metals, salts, neurotransmitters, enzymes, transcription factors, receptors, ligands, vitamins, minerals or metabolites, or any combination thereof. Biomarkers can be evaluated for concentration, expression, distribution, structure, folding, conformation, molecular interaction or chemical modification or the level or change of any combination thereof. The example of neurobiological markers includes amyloid beta protein, alpha synapse nucleus protein, tau protein, phosphorylated tau, neurofilament light chain (NfL), total tau fragment level, sarcoma fusion (FUS) protein, TAR DNA binding protein 43 (TDP-43), prions or neurotransmitters such as dopamine, or any combination thereof.Assessment can be performed by any suitable protocol, for example, Global Impression of Wandering (GIW), Revised Algase Wandering Scale-Community Version (RAWS-CV), Mini Mental State Examination (MMSE), Neuropsychiatric Inventory-Questionnaire (NPI-Q), Cohen-Mansfield Agitation Inventory-Community Version (CMAI-C), Center for Neurological Study-Lability Scale (CNS-LS), or Zarit Burden Interview (ZBI), or any combination thereof.

[0081] Patients treated with compositions disclosed herein may score poorly on cognitive scales such as Mini-Mental State Examination (MMSE). A threshold of ≤23 on MMSE can be set for dementia, wherein a score of ≤15 represents severe dementia. Patients may be treated with MMSE scores ≤23, including moderate dementia patients with MMSE scores of 16-23 and severe patients with MMSE scores ≤15. Once the patient's MMSE score is less than 9, they may have walking problems, and the treatment of patients with MMSE less than 5 may be omitted. Once MMSE drops below 15, the Severe Impairment Scale (SIB) may be a useful assessment. Treatment using compositions disclosed herein can improve cognitive function. In the early stages of treatment, patients can show an improvement of at least 3 points on MMSE and SIB. Relative to control patients, cognitive decline can be slowed down.

[0082] Wandering and other symptoms can be treated by the compositions and methods of the present disclosure. Wandering can be characterized by two areas. The first area can be movement, usually in the form of walking, unless the patient is disabled, for example, confined to a wheelchair. The second area can be problematic behavior, for example in the form of boundary crossing or path-finding problems or both. Such behavior can be reflected in the movement itself, such as pacing or running in circles. Behavior can involve inappropriate tracking of caregivers. A common problematic behavior is trying to escape or abscond. A certain amount of movement can also be considered as problematic behavior. A normal person can be in motion for about 10% of their waking time, and therefore movement exceeding this threshold amount can be considered as problematic behavior. When a patient is in motion for at least 20% of his waking time or more than 30% of his waking time, it can be considered that the patient experiences wandering. As the patient spends more time exercising, his behavior may become particularly problematic because the patient is at risk of exhaustion and therefore at risk of falling and serious injury. Wandering patients may be in motion for more than 40% or 50% of their waking time and more than 60%, 70% or even 80% of the time.

[0083] Wandering and other symptoms may be persistent or sporadic, and the composition of the present invention may be used to treat any population. Persistent wanderers may show excessive movement almost every day, typically at least 4 to 5 days per week. Sporadic wanderers may not show excessive movement usually, but may be sedentary with occasional movement, which is usually associated with absconding, boundary crossing, escape or pathfinding defects. The behavior shown by sporadic wanderers may be once a month when infrequent, or may be 2, 3 or even 4, 5, 6 or more times per week when frequent. Unlike persistent wanderers, sporadic wanderers do not spend an unusually large amount of time in motion. The patient treated may wander due to any form of dementia, and does not show pathfinding defects; such patients may be persistent or sporadic wanderers.

[0084] The compositions of the present disclosure may be used to treat wandering or other symptoms in patients with vascular dementia (VaD). The compositions may be used to treat mixed dementia, which has pathology that is not entirely attributable to VaD and overlaps with other dementias, such as Alzheimer's dementia (AD), etc. Any type or subtype of VaD may be treated, for example, VaD derived from various etiologies and pathologies associated therewith. The compositions of the present disclosure may be used to reduce or eliminate various symptoms and mood disorders associated with VaD.

[0085] The two main subtypes of vascular dementia are: i) large cortical infarcts or multi-infarct dementia (MID) and ii) small vessel disease-related dementia or subcortical vascular dementia. Subcortical vascular dementia may be caused by rupture of the vasculature in the subcortical white matter enriched areas of the brain. The International Classification of Diseases (10th Revision) (ICD-10) criteria for blood vessels clearly identify subcortical vascular dementia as a subgroup. Subcortical vascular dementia can be incorporated into the old entities "lacunar state" and "Binswanger disease (Binswanger disease)", and involves small vessel disease and hypoperfusion, resulting in focal and diffuse ischemic white matter lesions and incomplete ischemic damage. Most dementia patients (mainly non-VaD patients) may suffer from the first type, which affects the cortical area of ​​the brain and shows different defects caused by very different pathophysiological processes.

[0086] Large vessel cortical stroke and subcortical small vessel disease tend to produce different kinds of deficits. Characteristic symptoms of subcortical dementia can include forgetfulness, slowed thought processes, mild intellectual disability, apathy, dullness, depression (sometimes accompanied by irritability), memory loss, and inability to apply knowledge. People with subcortical dementia may suffer from mood disorders. Some people with subcortical dementia may experience other behavioral abnormalities, such as repetitive and compulsive behaviors. The manifestations of subcortical dementia may be more subtle and gradual in time, and are often described as deficits in executive function in subcortical dementia. These can include deficits in speed and "strategic" processing (e.g., attention, planning, and monitoring) in tasks such as memory tasks. Cortical vascular dementia may be associated with aphasia, apraxia, and amnesia.

[0087] The American Psychiatric Association distinguishes between mild and severe neurocognitive disorders. Mild neurocognitive disorder can be defined as a cognitive decline that differs from normal by one to two standard deviations in formal cognitive tests, which does not interfere with independence and is not due to delirium or other medical or psychiatric disorders. Severe neurocognitive disorder can be defined as a cognitive decline that differs from normal by two standard deviations or more in formal cognitive tests, which interferes with independence and is not due to delirium or other medical or psychiatric disorders. According to these criteria, VaD patients may suffer from severe neurocognitive disorders, such that the disorder interferes with their independence. Independence disorders can be assessed using scales that measure activities of daily living (ADL), including scales such as the Barthel Index and the Alzheimer's Disease Collaborative Study ADL scale. Patients who can be treated with compositions according to the present disclosure may have limited independence because these patients live in assisted living or memory care facilities and do not live in communities or family homes due to their morbidity.

[0088] The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V) provides a useful framework for identifying patients who can be treated with compositions according to the present disclosure. DSM-V provides a definition of dementia syndrome. Dementia syndrome includes objective cognitive or behavioral disorders in at least two of the following: memory; reasoning and handling complex tasks; visual spatial ability; language function; and personality, behavior or mannerisms. Dementia syndrome can also include a decline in function compared to previous levels and functional impairment. VaD dementia may be induced by cardiovascular events such as ischemic or hemorrhagic stroke or chronic cardiovascular diseases such as Binswanger's disease or lacunar dementia. VaD patients can be easily identified using the criteria of the National Institute of Neurological Diseases Stroke (NINDS) and the International Association for Research in Neuroscience (AIREN) (NINDS-AIREN criteria). The NINDS-AIREN criteria include the use of imaging to confirm vascular pathology. Patients identified according to the NINDS-AIREN criteria may be specifically included.

[0089] Compositions disclosed herein can be used for treating wandering or other symptoms in the disease with basic protein disease, and the disease comprises Huntington's disease, autism spectrum disorder, Down syndrome and dementia. Protein disease related dementia can be for example caused by Alzheimer's disease (AD), Lewy body dementia (DLB), frontotemporal dementia (FTD), head injury, normal pressure hydrocephalus, Creutzfeldt-Jakob disease, amyotrophic lateral sclerosis or Parkinson's disease or its any combination. When wandering occurs in the neurological symptom relevant to protein disease, this type of symptom can be regarded as wandering that protein disease is relevant, and can be used according to compositions treatment disclosed herein.

[0090] The common root cause of protein disease related wandering is usually dementia.Dementia can include a group of symptoms related to the decline of so serious memory and / or cognitive skills that adversely affect daily life activities.Recognizing this, the clear classification of dementia can be based on basic neuropathology.The feature of primary neurodegenerative dementia AD, DLB, Parkinson's disease dementia, FTD and the dementia related to prion disease (such as CJD) can be progressive protein disease, which is the accumulation of misfolded proteins causing neuronal loss, neuroinflammation and glial reaction.Neurodegenerative dementia can be distinguished by the position and property of misfolded protein accumulation.Therefore, the understanding of the applicable basic pathology of dementia can be used to understand the rational treatment of things regarded as different basic morbidities.

[0091] Compositions disclosed herein can be used to treat wandering or other symptoms associated with basic protein diseases. Protein disease-related dementia can refer to any form of dementia in which protein diseases are considered to be a part of the pathophysiology of dementia. Protein diseases are associated with lesions including aggregates or deposits of proteins that are not usually present in normal tissues. For example, Alzheimer's disease is associated with amyloid plaques composed of aggregates of Abeta4 and fibrillary tangles composed of deposits of phosphorylated tau. Frontotemporal dementia is associated with deposits of tau, TDP-43 and / or FUS. Pure vascular dementia can be independent of protein diseases. Both or either one of Alzheimer's disease and frontotemporal dementia can be included in the treatment regimen. Pure vascular dementia can be excluded from the treatment regimen. The compositions can be used to treat wandering in patients with conditions associated with abnormal deposits of huntingtin (HTT), FUS, TDP-43, tau, amyloid-β (e.g., amyloid-β42), optineurin, ubiquitin 2, superoxide dismutase 1, neurogenic locus notch homologous protein 3 (NOTCH3), or alpha-synuclein, or any combination thereof. Such deposits and the proteins they contain can be used as biomarkers.

[0092] The composition can be used to treat wandering or other symptoms in male or female human patients suspected of suffering from Parkinson's disease with the composition of the present disclosure. Synuclein disease is also called alpha-synuclein disease, which is a degenerative neurological disease characterized by abnormal aggregate accumulation of alpha-synuclein protein in nerves, nerve fibers or glial cells. Three major types of synuclein diseases include Parkinson's disease (PD), dementia with Lewy bodies (DLB) and multiple system atrophy (MSA). PD patients may experience motor symptoms, i.e. tremor, slow movement, stiffness and postural instability, as well as non-motor symptoms, including autonomic dysfunction, neuropsychiatric problems (e.g., mood, cognition, behavior or thinking changes), sensory impairment and sleep difficulties, including wandering.

[0093] The composition can be used to treat wandering or other symptoms of male or female human patients suspected of suffering from Lewy body dementia (DLB) with a composition according to the present disclosure. Lewy bodies are abnormal clumps of proteins (i.e., α-synuclein proteins, but tau proteins may also be included) that develop in nerve cells affected by PD, Lewy body dementia (DLB), and other conditions. DLB is a progressive and degenerative neurodegeneration, and is a synuclein disease like PD. Since the damage in the brain may be widely distributed, many functional domains may be affected. DLB can be distinguished from AD because short-term memory impairment can be an early and prominent feature in AD, while memory impairment may usually occur in the later stages of DLB. In addition, the severe atrophy of the hippocampus of AD may be more typical than that of DLB. Patients with DLB may experience changes in sleep (including wandering), behavior, cognition, movement, and autonomous body functions.

[0094] The composition can be used to treat wandering or other symptoms in a human patient suspected of having Huntington's disease with the composition of the present disclosure. Huntington's disease (HD) is associated with aggregates of the huntingtin protein (Htt) and is generally inherited. An individual has two copies of the huntingtin gene (HTT), which contains a trinucleotide repeat of cytosine-adenine-guanine (CAG). Individuals with 35 or fewer CAG repeats in the HTT gene are not affected by HD, individuals with 36-39 CAG repeats may or may not be affected by HD, and individuals with 40 or more CAG repeats are generally affected by HD. Htt aggregates accumulate to form inclusions within cells and disrupt neuronal function, and can be cytotoxic.

[0095] The composition can be used to treat wandering or other symptoms in male or female human patients suspected of having a disease with basic 4R tauopathy with a composition according to the present disclosure. Preferred 4R tauopathy comprises PSP, CBD, AGD, GGT, which is characterized by the accumulation of phosphorylated 4R tau aggregates in neurons and certain glial cells in neuropathology. Depending on the type and location of the specific pathology, 4R tauopathy can show many different clinical syndromes. There may be significant overlap between PSP and CBS (clinical manifestations of CBD), and there may also be significant similarities in neuropathology, which shows that they are highly related in the case of not being the manifestation of the same symptom. By autopsy, brain tissue can be examined, and a conclusive diagnosis of 4R tauopathy can be obtained. Based on this, patients who can be treated with a composition according to the present disclosure can be regarded as having a "probable" or "possible" disease. These patients can be regarded as suffering from 4R tauopathy, even if it has not been confirmed pathologically. The treatment of wandering of patients suffering from 4-R tau disease can be regarded as the treatment of patients suffering from the approximate or possible disease, and the treatment of patients with confirmed pathology, which should become possible in the future, without the need to use, for example, imaging or biomarkers to perform autopsy. Similarly, comorbidities may also exist in patients treated with compositions as described herein. These comorbidities include Alzheimer's disease-related pathology (including cerebral amyloid angiopathy), Louis-related and trans-reacting DNA binding protein 43 and other protein diseases. Cerebrovascular disease (including small vessel disease) is a common comorbidity.

[0096] The diagnostic criteria for progressive supranuclear palsy (PSP) can be followed. Probable PSP refers to patients with a confirmed diagnosis. Various clinical manifestations of probable PSP can be distinguished, depending on the main clinical features. These include, for example, PSP with Richardson syndrome (PSP-RS); PSP with progressive freezing of gait (PSP-PGF); PSP with predominant parkinsonism (PSP-P); PSP with predominant frontal manifestations (PSP-F); PSP with predominant oculomotor dysfunction (PSP-OM); PSP with predominant speech / language impairment (PSP-SL); PSP with predominant CBS (PSP-CBS); PSP with predominant postural instability (PSP-PI).

[0097] The clinical features of PSP can be divided into the following functional areas: oculomotor dysfunction, postural instability, dyskinesia, and cognitive dysfunction. The most highly relevant ("level 1") clinical features of PSP can be vertical supranuclear gaze palsy, repeated unprovoked falls within 3 years, progressive gait freezing within 3 years, and speech / language disorders (non-fluent / agrammatical variants of primary progressive aphasia or progressive apraxia of speech). Also highly relevant to PSP ("level 2" clinical features) can be slow vertical saccade speed, a tendency to fall in a pull test within 3 years, Parkinson's disease, hypokinetic-rigid, major axial and levodopa resistance, and frontal lobe cognitive / behavioral performance. Equally significant but less relevant ("level 3" clinical features) can be frequent square wave jerks or "paleopaxia"; more than two steps backward in a pull test within 3 years, Parkinson's disease, accompanied by tremor and / or asymmetry and / or levodopa response, and corticobasal syndrome. Patients who can be treated with the compositions described herein can have at least one level 1 or 2 clinical feature. Many patients may have a combination of clinical features extracted from Grade 1, Grade 2, and Grade 3 clinical features. Various types of patients with corticobasal degeneration may be treated with compositions according to the present disclosure. Patients with presumably corticobasal syndrome and / or presumably corticobasal degeneration may be treated.

[0098] There may be argyrophilic grain disease (AGD) without any unique clinical features. AGD can be manifested as AD, so AGD can be considered to be clinically identical to AD, but there is evidence that patients lack amyloid pathology. By checking the CSF level of beta-amyloid 42 and / or using beta-amyloid PET imaging, amyloid pathology can be excluded. Compared with other 4R tauopathies, AGD lacks acetylated tau protein in its inclusions. Like AGD, globular glial tauopathy (GGT) may lack a clear clinical syndrome, which manifests as a combination of frontotemporal dementia, motor neuron disease and / or extrapyramidal features. The identification of GGT patients can involve the use of imaging, biomarkers and differential diagnosis to eliminate other pathologies. The wandering of male or female human patients suspected of suffering from dementia caused by stroke can be treated with the compositions described herein. The dementia associated with cerebrovascular accident (CVA or stroke) can be referred to as vascular dementia.

[0099] Compositions described herein can be used to treat wandering or other symptoms in male or female human patients suspected of having dementia caused by traumatic brain injury (TBI). TBI is an environmental risk factor for dementia. There may also be a genetic component that affects dementia caused by TBI. A history of TBI and the inheritance of the APOEε4 allele are associated with a 10-fold increase in the risk of dementia, while APOEε4 without TBI only causes a 2-fold increase in risk. Autopsy studies have shown that up to one-third of patients with prolonged survival after a single TBI have beta-amyloid plaques and neurofibrillary tangles (NFTs). Patients who experience multiple TBIs, such as professional athletes who suffer multiple concussions, may experience dementia associated with chronic traumatic encephalopathy (CTE), which was previously known as dementia pugilistica or dementia pugilistica. CTE autopsies show overall atrophy of the brain, with thinning of the corpus callosum and enlargement of the ventricles and cavum septum pellucidum.

[0100] The compositions of the present disclosure can be used to treat wandering or other symptoms in patients diagnosed with amyotrophic lateral sclerosis (ALS) and other motor neuron diseases. Other motor neuron diseases include, for example, X-linked spinobulbar muscular atrophy (Kennedy's disease), adult Tay-Sachs disease, spinal muscular atrophy, multifocal motor neuropathy with conduction block, primary lateral sclerosis, and familial spastic paraplegia. Upper and lower neuron degeneration can be shown. The symptoms of ALS and other motor neuron diseases can depend on whether the corticospinal neurons, lower motor neurons, or both are affected and the degree of degeneration. Symptoms can include, for example, muscle twitching of the arms, legs, shoulders, or tongue; muscle spasms; muscle tightness and stiffness (spasticity); muscle weakness affecting the arms, legs, neck, or diaphragm; slurred speech with nasal sounds; or difficulty chewing or swallowing; or any combination thereof. The compositions of the present disclosure can further include one or more additional APIs (e.g., riluzole, edaravone, or both) or be administered together with them to patients diagnosed with ALS or another motor neuron disease.

[0101] The present disclosure also encompasses methods of making the compositions of the present disclosure. Any suitable manufacturing process may be used to make the compositions. The compositions may be made as concentrates and then diluted prior to administration. Dry or liquid concentrates may be made. The compositions may be made into separate mixtures for mixing prior to administration to a patient. The present disclosure also provides for the use of rho kinase inhibitors for making compositions, for example for the treatment of one or more neurodegenerative diseases. The present disclosure further provides for the use of rho kinase inhibitors for the treatment of one or more neurodegenerative diseases in the compositions of the present disclosure.

[0102] Examples

[0103] The present disclosure is further clarified by the following non-limiting examples, which are illustrative examples of the compositions of the present disclosure.

[0104] Example 1

[0105] The solubility and stability of aqueous compositions including fasudil were evaluated. Fasudil hydrochloride hemihydrate was dissolved in water (without buffer) to obtain a concentration ranging from 16.15 to 19.77 mg / ml, and 0.05M HCl was used to adjust to various pH values ​​(HCl was not used for F22). The samples were stored at 60°C for 42 days. As shown in Table 1, there was no significant change in fasudil concentration or pH in any sample. These results show that unbuffered fasudil at 16-20 mg / ml is stable in the range of pH 4 to pH 6.

[0106] Table 1

[0107]

[0108]

[0109] Example 2

[0110] The stability of aqueous compositions of fasudil containing citrate buffer and EDTA was evaluated. The following formulations were prepared to evaluate the effect of EDTA on the stability of fasudil in 0.05 M citrate buffer. The samples were stored at 60 ° C for 36 days. As seen in Table 3, neither the samples with or without EDTA showed any changes in pH or fasudil concentration. These results indicate that fasudil is compatible with EDTA in citrate buffer.

[0111] Table 2

[0112]

[0113] Table 3

[0114]

[0115] Example 3

[0116] The use of sweeteners in aqueous compositions was evaluated. Upon tasting various fasudil solutions, the drug was found to have a very unpleasant bitter taste. Various methods for preparing more palatable drug formulations were evaluated. The formulations set forth in Table 4 were prepared, containing a sweetener (acesulfame potassium) and strawberry flavoring.

[0117] Table 4

[0118]

[0119]

[0120] The formulation still had a bitter taste, but the one subject who tested it could tolerate the bitter taste. The bitter taste eventually subsided. There was no nausea or vomiting due to the bitter taste. The formulation was stored at 60°C for 28 days and tested for impurities. The total impurities were 0.10% when stored at 60°C for 28 days, indicating that Fasudil was compatible with the various ingredients in the formulation. The formulation was adjusted to the desired consistency to obtain the formulation in Table 5.

[0121] Table 5

[0122]

[0123] The pH of both formulations was further adjusted with 1 N NaOH to obtain the pH values ​​in Table 6. These four samples were tested and most subjects could not tolerate the taste. These results indicate that the sweetener was not effective enough to mask the taste.

[0124] Table 6

[0125] preparation pH 33A Sub-Batch 1 4.27 33A Sub-Batch 2 6.76 34A Sub-Batch 1 4.28 34A Sub-Batch 2 7.04

[0126] Example 4

[0127] Evaluation of bitter masking agents. 1.6 g of fasudil was dissolved in water to make 100 mL of a stock solution (16 mg / mL, Formulation 35A). 3.0 mL of sample was aliquoted into vials and various agents were added as indicated in Table 7. Each sample was tasted and the bitterness was rated from 1 to 10, with 10 being the most bitter.

[0128] Table 7

[0129] Pharmacy Dosage Stock solution weight grade# observe HPBCD 201.4mg 2.995g 7 Moderately bitter solution SBEBCD 206.9mg 2.9868g 3 Less bitter astringent caffeine 54.3mg 3.01g 9 Very bitter NaCl 28mg 3.04g 5 Salty, less bitter HPMC E5 34mg 3.04g 7 Moderate bitterness Menthol 17.9mg 2.9365g 7 Moderate bitterness Na CMC 43mg 3.06g 5 Bitter taste, CMC is not completely dissolved Polycarbophil 28mg 3.00g 7 Moderate bitterness Glycine 200.2mg 3.02g 2 Less bitter

[0130] Bitterness is rated from 1 to 10, 10 being the most bitter HPBCD-Hydroxypropyl β-cyclodextrin

[0131] SBEBCD-sulfobutyl ether β-cyclodextrin

[0132] NaCl - Sodium Chloride

[0133] Na CMC–Na CMC-Sodium carboxymethyl cellulose

[0134] Based on the data, SBEBCD and glycine appeared promising and were further tested.

[0135] Table 8

[0136]

[0137] Addition of varying amounts of glycine and SBEBCD showed no significant change in bitterness. In the case of glycine, some bitterness remained in the mouth after rinsing with water. A combination of SBEBCD and glycine (Formulation 36A; Table 9) was investigated to see if a mixture of the two best agents, which have yet to be identified, could provide better masking.

[0138] Table 9

[0139] Element % Amount in 100mL Fasudil HCl 1.6 1.6044g Acesulfame Potassium 0.2 0.2178g Sodium chloride 0.7 0.7051g Disodium EDTA 0.2 0.2467g glycerin 10 10.0251g Mannitol 10 10.0300g Xanthan gum 0.4 0.4049g D&C Yellow 5 0.05 50.1mg Glycine 5 5.03g SBEBCD 7.5 7.49g water 64.35 64.36g。

[0140] Formulation 36A was aliquoted into vials and tested in small groups. The bitterness rating was 2, qualitatively better tasting than Formulations 33A or 34A, but still with an easily recognizable bitter taste.

[0141] Example 5

[0142] Additional bitter taste masking approaches were explored. Evaluation of Alginic Acid Formulations. Alginic acid was first used as an ion pairing and gel forming agent for taste masking by preparing the composition in Table 10 (Formulation 38).

[0143] Table 10

[0144]

[0145]

[0146] A corresponding placebo formulation (lacking fasudil) was prepared and both formulations were tasted. Formulation 38 tasted much better than any of the previous formulations, but it was still easily distinguishable from the placebo.

[0147] The next step is to increase the sweetener and alginic acid content, eliminate sodium chloride, and study various pH. The bitter taste is still obvious. In some instances, formulation 49A is 3mg / mL, so it will use 10mL to deliver 30mg. It has a very pleasant taste for at least one tester. The two 6mg / mL formulations taste slightly bitter, much better than 16mg / mL, but not much different from each other. Table 11 shows the formulations with increased alginic acid and sweeteners.

[0148] Table 11

[0149] Element% 47A 48A 49A 50A Fasudil HCl 1.6 0.6 0.3 0.6 Sodium chloride 0.2 0.2 0.2 0.2 Disodium EDTA 0.2 0.2 0.2 0.2 glycerin 10 10 10 10 Mannitol 10 10 10 10 Transparent Xanthan Gum 80 0.3 0.9 0.9 0.9 alginic acid 3.0 3.0 3.0 3.0 Acesulfame Potassium 0.2 0.4 0.4 0.6

[0150] Ion exchange resins were studied. It was apparent that alginic acid alone was not sufficient to mask the bitter taste. A strong cation exchange resin was studied. A 100 g sample of cation exchange resin (same chemistry as AMBERLITE IRP 69, but with sulfonic acid as exchange sites) was used to form drug-resin complexes in situ. Table 12 shows formulations 51A-52A formulated with ion exchange resins.

[0151] Table 12

[0152]

[0153]

[0154] A group of tasters agreed that these preparations were greatly improved over previous preparations and that they were palatable. Feedback on these preparations included that colorants were not needed because the current color looked "medical". Further, no flavoring was needed and the flavor was accepted. All thought that preparation 52A was too thick. One person had an aftertaste for both preparations. One person tasted the bitterness of preparation 51A, but preparation 52A did not. This person also preferred the texture of 52A. Alginic acid may have pulled out some fasudil from the resin in preparation 51A, exposing it to solvent. Then consider the comparison of "with and without alginic acid" and the attempt to match the consistency. The data are presented in the table below. Table 13 describes preparations 53-55 with increased xanthan gum content and eliminated alginic acid. Table 14 describes the viscosity values ​​of preparations 53-55. Table 15 describes another survey of xanthan gum content. Table 16A describes the viscosity values ​​(IDDSI syringe test) of various xanthan gum contents. Table 16B illustrates viscosity values ​​(Cannon viscometer) for various xanthan gum contents.

[0155] Table 13

[0156] Ingredients pH 4.0 w / NaOH 53P 54P 55P Fasudil HCl - - - Sodium chloride 0.2 0.2 0.2 Disodium EDTA 0.2 0.2 0.2 glycerin 10 10 10 Mannitol 10 10 10 Transparent Xanthan Gum 80 0.5 0.4 0.6 Ion exchange resin 4.68 4.68 4.68 Acesulfame Potassium 0.3 0.3 0.3

[0157] Table 14

[0158]

[0159] Table 15

[0160]

[0161] Table 16A

[0162]

[0163] Table 16B

[0164]

[0165] Based on the viscosity data, 0.3%-0.4% xanthan gum appears to produce a palatable and acceptable consistency. Higher drug loadings were investigated while varying the resin content and keeping the xanthan gum in the range of 0.3%-0.4%. Table 17 illustrates the drug loading studies for taste masking.

[0166] Table 17

[0167]

[0168] Most feedback considered formulations 61-63 (drug loading 0.3%-2.4%) to be palatable. However, the formulations were observed to sediment upon storage and did not redisperse well. Therefore, a neutral suspension (suspension) formulation was investigated. Table 18 lists the formulations used to investigate the suspension.

[0169] Table 18

[0170]

[0171] The formulations were stored at 60°C overnight and then observed for sedimentation and redispersion. Table 19 shows the effect of the suspending agent on physical stability.

[0172] Table 19

[0173] preparation# As is As bottom Slight bottom shaking Shake vigorously 67(XG) Sediment Sticky sediment Partial redispersion Redispersed small sediments 68(MC) Suspension Flocculent Easy to redisperse Suspended foam 69(HPMC) Suspension Sediment Partial redispersion, Suspended foam 70(Povidone) All settlement Powdered sediment Easy to redisperse Powders tend to settle 71(XG#) Sediment Sticky sediment Partial redispersion Redispersed small sediments

[0174] Based on the data from Table 19, methylcellulose seems to be promising. Then consider the following method. Dissolve the drug in water. Add resin to the solution. Adjust the pH to 4. Filter and dry the resin. Measure the drug concentration on the filtrate. Use the resin to prepare suspensions (a) MC, (b) xanthan gum and (c) 5% crospovidone and 5% glycerol to determine whether deposition will be reduced or eliminated. Formulations are also prepared with unfiltered crospovidone and compared. Formulations 72-76 on the effect of suspending agents on physical stability are shown in Table 20.

[0175] Table 20

[0176]

[0177] The procedure for preparing formulations 72-76 is as follows: first weigh water in a beaker (about 5 ml), then dissolve the drug in water (18 mg / ml). Weigh about 90 mg of the drug. Then add the resin to the solution. (Resin: drug ratio 2.5). Add about 225 mg of resin. Adjust the pH to 4. Filter the solution using 0.45 micron filter paper. Measure the drug concentration on the filtrate. Resuspend the drug-resin complex. Prepare a suspension using the drug-resin complex with a) methylcellulose (MC), b) xanthan gum, and c) 5% crospovidone and 5% glycerol to see if the deposition is reduced or eliminated. All formulations are divided into two vials, and one is stored at 60°C and the other is stored at room temperature. The observations are as follows: the formulation with crospovidone shows sedimentation, but no viscous sediment is formed. The resin-drug complex can be easily resuspended. No gel is formed, and the combination of methylcellulose and crospovidone is considered. The previous batch of MC was too thick, and the percentage of MC in the formulation was considered to be reduced. Two formulations were prepared with different percentages of MC and crospovidone. The resin to drug ratio was set to 2.5 and the concentration of the drug was set to 18 mg / mL. Table 21 shows the effect of the methylcellulose and crospovidone content of the formulation on physical stability.

[0178] Table 21

[0179] Element% 77A 78A Fasudil HCl 1.8 1.8 Crospovidone 2.0 4.0 MC 1.0 0.8 Acesulfame Potassium 0.3 0.3 Ion exchange resin 4.5 4.5 pH 3.98 3.90 Distilled water Moderate Moderate

[0180] After 4 days, the sample changed color to light yellow at 60°C. The sample was white at 25°C. All four samples showed sedimentation of the resin, but the resin could be resuspended when shaken. The bottom of the vial became clear. Formulation 78A showed that the resin adhered to the inner wall of the vial.

[0181] Weak cation exchange resins were investigated. AMBERLITE resin samples were received from Coloron. AMBERLITE Sulfonate IRP 69 (strong resin, same chemistry as previously used resin, but with sodium sulfonate groups), AMBERLITE Polacrilin Potassium IRP 88 (weak resin, -COOK), and AMBERLITE Polacrilin IRP 64 (-COOH). The AMBERLITE resins (supplier: Colorcon; manufacturer: DuPont) investigated are set forth in Table 22.

[0182] Table 22

[0183]

[0184] Fasudil bound to resins was studied. When the resin:API w / w ratio was 3 or greater, both IRP 69 and IRP64 bound >99% of fasudil, while IRP 88 bound >92% under the same conditions. IRP 69 is darker in color. It was observed that the formulation with IRP 69 changed color and sedimented, and was not easily redispersible (forming a sticky sediment). After storage overnight at 60°C, the formulations with IRP 64 and 88 were easily redispersible. Both resins are considered for further formulation development. IRP 64 and IRP 88 are weak cation exchange resins with carboxylic acid groups, so pH can affect their ion exchange capacity. A pH of at least 6 is considered to fully utilize their capacity, and the pH target for the formulation is between 6 and 7.

[0185] Table 23

[0186]

[0187] Compared with the formulation (82) with crospovidone, the formulation (81) with MC is more viscous. The formulation vials are sealed and stored at 60°C. After overnight storage, formulation 82 shows powder sedimentation, and formulation 81 is a good suspension. Then focus on IRP 88. When gently shaken, in both formulations 81 and 82, the suspensions are well mixed and no sticky sediment is observed at the bottom. Because formulation 81 is very viscous, some powder adheres to the inner surface of the bottom of the vial. This vial is compared with the vial of formulation 79. Formulation 79 has both MC and crospovidone. Crospovidone seems to help disperse the powder in the formulation. Both formulations are vortexed and ultrasonicated during preparation, but formulation 81 shows very few small gel pieces. A homogenizer (84) is used and compared with the use of vortex (83).

[0188] Formulations 83 and 84 were subjected to the IDDSI flow test (https: / / iddsi.org / IDDSI / media / images / Testing_Methods_IDDSI_Framework_Final_31_July2019.pdf). The plunger was removed from the 10-mL syringe (61.5 mm from the zero line to the 10 mL line), and the syringe was then filled with the formulation when the nozzle was clogged. The volume of fluid remaining in the syringe after 10 seconds of free flow was determined. In the case of formulation 83, the flow was stopped due to a small gel block in one reading. The average remaining volumes for formulations 83 and 84 were 4.7 mL and 5.1 mL, respectively. The dynamic viscosity of the formulations was determined using a Canon Viscometer #300. The viscosity values ​​for formulations 83 and 84 were found to be 78 cSt and 112 cSt, respectively.

[0189] Formulation 84 was tasted and no bitterness was observed. It felt like a smooth gel. Formulation 83 showed a few small gel pieces. In both cases, the insoluble material was well suspended and did not settle quickly. Formulation 83 samples were stored at 60°C. Formulation 84 was stored at 5°C, 25°C, and 60°C. The physical stability appeared to be acceptable. Formulation 84 appeared to be a satisfactory formulation. Preliminary studies were conducted to investigate the levels of methylcellulose, crospovidone, and IRP 88, keeping the drug loading at 18 mg / mL.

[0190] Studies investigating suspending agent and resin content were performed. Neutral suspending agents crospovidone and methylcellulose (MC) showed the most promising formulations from a sedimentation and redispersion point of view. Recommended low and high settings: crospovidone: 0.5% and 2.0%; MC: 0.8% and 1.4%; AMBERLITE IRP 88: 4.5% and 6.3%. Drug loading was 1.8% (18 mg / mL). pH = 6. Samples were placed at 60°C and checked for physical stability. The effect of pH was considered to be minimal when the pH was between pH 6-7.

[0191] Table 24

[0192]

[0193] Example 6

[0194] Another study was conducted to investigate resins and suspending agents: three resins (A-IRP 64, polacrilin, COOH) (B-IRP 88, polacrilin potassium, COOK) and (IRP-69, sulfonate) were investigated along with three different types of viscosity building agents (a-1.2% methylcellulose, MC), (d-0.3% xanthan gum, XG) and (f-1.2% MC + 0.5% povidone 90F).

[0195] Table 25

[0196]

[0197]

[0198] The formulations listed in the above table were prepared and tested by the IDDSI (syringe) flow test. During the test, the plunger was removed from a 10 mL plastic syringe (61.5 mm from the zero line to the 10 mL line). The syringe nozzle was covered and the syringe was filled with 10 mL of the formulation. The nozzle was released and the flow stopped at 10 seconds. The remaining formulation was measured inside the syringe. The deposition of the formulation was also measured using a syringe. The syringe and graduated cylinder test results after pH adjustment are set forth in Table 26. The pH of the polacrilin and polacrilin potassium samples was adjusted to about 6.2. The pH of the sulfonate sample was adjusted to about 4.0.

[0199] Table 26

[0200]

[0201] * Resin is better suspended in Xanthan Gum (XG) samples

[0202] # There is no cloudy layer in the sample with sulfonate resin - this means the top layer is clear and settles faster.

[0203] The thicker the solid layer, the more sedimentation. Ideally, all should remain as one turbid layer. But sedimentation produces a bottom solid layer, an intermediate turbid layer, and a top clear layer. All samples containing MC show resin sedimentation as a solid sedimentation layer. The turbid layer is not so white compared to the layer with XG. In the samples with MC and povidone, the top clear layer is much larger. The sulfonate sample shows only two layers-the bottom sedimentation layer and the top clear layer. Based on the IDDSI (syringe) test, all samples with MC are "slightly thick", and the samples with XG are "slightly thick". Although the MC samples have high viscosity, the resin settles in the samples with MC. The vials of these samples show similar sedimentation. All vials were gently shaken 10 times. In all samples with MC, the solid layer at the bottom was not redispersed. In the samples with XG, the sedimentation layer is easily redispersed, and the bottom of the vial can be visible. Consider using a mixture of MC and XG to avoid sedimentation problems.

[0204] Table 27

[0205]

[0206] The IDDSI test results for FAS formulations 95, 96, and 97 are shown in Table 28. The values ​​are the volume of formulation remaining in the syringe after 10 seconds (mL).

[0207] Table 28

[0208] preparation Test 1 Test 2 average value 95A 7.0 7.0 7.0 96A 7.2 7.4 7.2 97A 9.0 9.0 9.0

[0209] More formulations using the xanthan gum / MC combination as suspending agent were prepared as described in Table 29.

[0210] Table 29

[0211]

[0212]

[0213] Formulations 98A-100A were stored at 5°C and 40°C for 3 days and tested for physical stability.

[0214] Table 30

[0215] preparation 5℃ 40℃ 98A with MC Suspension, no cake formation The powder settles and forms a gel 99A with Xanthan Gum Suspension, no cake formation Suspension, no cake formation 100A with MC and xanthan gum Suspension, no cake formation Suspension, no cake formation

[0216] Based on the data, Formulations 101A and 102A were prepared and tested for stability.

[0217] Table 31

[0218] Element Percentage of 101A Percentage in 102A Fasudil HCl 1.8 1.8 glycerin 10 10 Acesulfame Potassium 0.25 0.25 Transparent Xanthan Gum 80 0.4 0.2 Methylcellulose A15C - 0.5 Polacrilin IRP 64 5.4 5.4 Sodium Benzoate 0.2 0.2 Mint flavoring 0.05 0.05 Distilled water Up to 100mL Up to 100mL

[0219] 1N NaOH was used to adjust the pH. The final pH after homogenization of formulations 101A and 102A was 6.22 and 6.34, respectively. 100 mL of each formulation was prepared. 20 mL Type I glass injection vials were used to fill 10 mL of the formulation. For each formulation, nine (9) vials were filled for stability studies. Stability data for up to 3 months at 25°C / 60%RH and 40°C / 75%RH showed that the formulations were chemically stable. Table 32 describes the suspension stability at 25°C / 60%RH. Table 33 describes the suspension stability at 40°C / 75%RH.

[0220] Table 32

[0221]

[0222] *Slight fluctuations in measurements are believed to be due to homogeneity of smaller sample size.

[0223] **Peak area percentage. Other peaks are excipient peaks.

[0224] Table 33

[0225]

[0226] Observe microbial growth, this can be solved by including antimicrobial in preparation.In the time of five months, 101A (xanthan gum only) is deposited as cake, and is not easy to disperse again.102A (xanthan gum / MC combination) is easy to disperse again.Based on these results, preparation contains xanthan gum and methylcellulose and preservative.

[0227] Example 7

[0228] Effect of pH on the binding of Fasudil to AMBERLITE IRP 69 resin, an ion exchange resin containing sulfate functional groups. Several batches of IRP 69 and IRP 64 resins were prepared with drug concentrations of 25 mg / mL and 50 mg / mL. The resins were added to the drug solutions and stirred for 30 minutes. The pH of the supernatants were observed to be 7.55 and 2.75, respectively. The drug concentration in the supernatant of the IRP 69 resin was very low, about 250 ug / mL, indicating strong binding of FAS to the IRP resin. The drug:resin ratio was 1:4. At higher pH, the reduction in fasudil binding to the resin is due to protonation of fasudil. Table 34 depicts the composition of the various samples used in the study. The results are in Figure 1 Figure 2. Effect of pH on the binding of fasudil to IRP 64 resin. Figure 2 At lower pH, the resin is not fully deprotonated and therefore the binding efficiency is reduced.

[0229] Table 34

[0230]

[0231]

[0232] The study used an improved method to extract fasudil from AMBERLITE IRP 69. The test was performed in duplicate. About 125 mg of the drug-resin complex was added to a 100 mL volumetric flask, and 500 mg of NaCl, 50 mL of a diluent containing 40% acetonitrile, and 60% of 0.01 N sodium hydroxide were added. The flask was placed on a wrist shaker and allowed to shake for 30 minutes. Before HPLC analysis, the sample was taken out and centrifuged. The two flasks were further shaken for another 30 minutes. The drug solution was shaken vigorously in the flask. Table 35 lists the extraction values ​​for the two samples. The extraction seems to be satisfactory, and wrist shaking for 30 minutes seems to be sufficient. Table 35 shows the extraction of fasudil from sulfonate resin by the wrist shaking method.

[0233] Table 35

[0234]

[0235] The S1 (resin:drug complex 4:1) formulation is listed in Table 36 below.

[0236] Table 36

[0237] Element Theoretical amount, g Actual amount, g FAS, 25 mg / mL solution 50.15 50.23 Resin, sulfate 5.00 5.02 Final pH - 7.55

[0238] Table 37 lists the various parameters studied. Table 38 lists the different dissolution media studied.

[0239] Table 37

[0240]

[0241]

[0242] Table 38

[0243] condition 1 2 Dissolution medium 900mL fresh water 900 mL 25 mM buffer, 0.9% NaCl, pH 7.4

[0244] Release data in Figure 3 Shown in. Figure 3 The dissolution of a spray containing fasudil under two different conditions over time is depicted. The low release in aqueous media is due to the lack of ion exchange with fasudil, so fasudil remains bound to the resin.

[0245] Example 8

[0246] The taste threshold concentration of fasudil was tested. Table 39 lists the concentration of the fasudil aqueous composition and the perception of the fasudil aqueous composition by the first taste tester. Table 39 lists the concentration of the fasudil aqueous composition and the perception of the fasudil aqueous composition by the second taste tester.

[0247] Table 39

[0248] Fasudil concentration mg / mL Taste Perception 1.5 Dislike 1.0 Perceptible but tolerable 0.5 Light 0.1 Light 0.05 Unable to perceive

[0249] Table 40

[0250] Fasudil concentration mg / mL Palatability* bitterness* Aftertaste* 0.5 2 7 5 0.1 5 1 1 0.05 not applicable not applicable not applicable

[0251] *Scale of 1-10, 10 being the worst tasting for bitter aftertaste and 10 being the best tasting for palatability.

[0252] Example 9

[0253] Examples of making liquid suspensions are provided. Cosolvents can be used as adjuvants for gel formation. Making gels using xanthan gum, methylcellulose, carbomer and other polymers can be a laborious process. The procedures described herein can reduce the processing time for making gels, and subsequently reduce the processing time for making suspension formulations. Cosolvents (e.g., PEG 300, PEG 300, propylene glycol, glycerol and ethanol) can be used as adjuvants for gel formation. First, dry xanthan gum and polymers are moistened with cosolvents, and water is added to the cosolvents under constant stirring. These can include one or more wetting agents; gums are essentially thickening agents. Examples of wetting agents that can be used include glycerol and alcohol. For example, a 2% ethanol solution can be used. The addition of cosolvents prevents lumps from forming, and the gel forms quickly. When water and other excipients are added and stirred, the gel decomposes and forms a suspension-this product is an example of an oral suspension formulation. The oral suspension formulation can be in the form of a thickened solution.

[0254] Can adopt " one pot " process or " two pot " process or both.In one pot process, single container is used to combine medicine, gum and resin.In two pot process, medicine and resin are first combined in first pot, then transferred to second pot and mixed with other ingredients.Therefore, preparation can be prepared by batch process using one pot or two pot process.In one pot process, product can be prepared in one tank.First, gum and polymer are moistened with cosolvent, and then gel can be prepared.Water, medicine, resin and other excipients are added in the same container.In two pot process, in first tank, drug solution can be mixed with resin to load medicine into resin.In second tank, gel of xanthan gum and polymer (for example, cellulose ether) is prepared.The contents of two tanks are mixed to provide final drug product.Product can be successfully prepared using either process.

[0255] One or more resins can be used as is, or can be activated with acid, base or both. The resin has a carboxylic acid group, which can be activated with hydrochloric acid. The acid opens the binding sites on the surface of the resin particles and is also located in the pores of the resin. The resin can be neutralized, for example, using sodium hydroxide. The activation of the resin also helps to enhance the interaction between the resin and the drug. Even if the resin is not activated, the drug molecules will eventually bind to the binding sites on the resin, and a satisfactory formulation can be prepared.

[0256] The advantage of these methods is that they can produce effective drug binding relatively independent of the particle size of the resin. The resin particles may be insoluble in water. The resin particles are porous. The binding sites on the resin can be on the surface and mostly inside the pores. Therefore, no significant effect of resin particle size on drug loading and release is observed.

[0257] Soluble excipients with carboxylic acid groups can be used in the formulation. Such excipients are in addition to carboxylic acid or sulfonate containing resins used for drug binding. An example of such an excipient is carbomer. The resin has carboxylic acid groups or sulfonate groups with which the fasudil drug ion is paired. There are many excipients with ionizable carboxylic acid groups, such as sodium carboxymethylcellulose, alginic acid, polyacrylic acid, polymethacrylic acid, and carbomer. Drugs have been observed to bind to these cation exchange polymers. Adding these to the formulation will serve two purposes: increasing viscosity through gelation and reducing the amount of resin required to block the bitter taste.

[0258] Example 10

[0259] Check the drug: resin ratio to determine their impact on the total binding of the drug to the resin. There is usually a certain amount of drug in a dissolved state and unbound in the supernatant, i.e., drug without resin, which may cause bitterness. Advantageously, it can be minimized, for example, by using a soluble excipient (e.g., carbomer). Carbomer can, for example, serve as a second taste masking agent. Alginate can be used as a supplement or alternative to alginate. Using a second taste masking agent can mean using less of the first taste masking agent. The ratio of drug to resin is a parameter of taste masking effectiveness. Evaluate different drug: resin ratios. The loading capacity of Amberlite IRP 64 Polarilex resin is not less than 10meq / g (DuPont TM AmberLite TM Ion Exchange Resins Product Data Sheet, April 2021). This corresponds to a fasudil to resin w / w ratio of about 3:1. In practice, more resin may be used to mask the taste of fasudil. Drug to resin ratios ranging from about 1:2 to about 1:4.5 by weight may be employed, with a ratio of 1:3 giving generally acceptable results.

[0260] Example 11

[0261] For these example formulations, the resin was used as is, and formulation 142 was not activated. Before loading the drug for batches 157 and 163, the resin was activated with 0.1N HCl. All three batches 142, 157 and 163 were prepared by a two-pot process. For formulation 142, due to the lower strength and lower resin content, the gum and methylcellulose can be slightly higher. Formulation 157 is the opposite. The amount of gum and methylcellulose can be reduced. Formulation 163 is just right. In some cases, the taste threshold of the supernatant can be 0.3-0.4 mg / mL. Formulation examples are set forth in Table 41.

[0262] Table 41

[0263]

[0264] Example 12

[0265] Another example of a suspension formulation produced according to the present disclosure is set forth in Table 42 for Formulation 172. Formulation 172 shows that xanthan gum is not the only gum that can be used to achieve a stable palatable formulation.

[0266] Table 42

[0267] Preparation ID (% w / w) 172 Fasudil HCl hemihydrate 2.31 glycerin 10 Acesulfame Potassium 0.25 Gellan Gum 0.35 Methylcellulose A15C 0.3 Zuckery IRP 64 6.92 Methylparaben 0.25 Sodium Propylparaben 0.03 Alcohol 200proof 2 water Moderate Palatability Acceptable

[0268] These concentrations are examples only, and the taste threshold concentration may be selected based on various factors described herein and other factors understood in the art.

[0269] Example 13

[0270] Ion exchange resins are used to mask the taste of fasudil. Different immediate-release and sustained-release oral solid dosage forms can be produced by drug-loaded ion exchange resins. For example, a "spray" can be produced. After fasudil is loaded onto the ion exchange resin, the resulting drug-resin complex can be sprayed on soft food. Drug loading on the resin can be achieved by a batch process or a column process. The drug-resin ratio can be 3:1 to 1:10. The drug-resin complex can be dried by any conventional drying process. The dried drug-resin complex can be administered as a spray with soft food. The drug-resin complex can be granulated to prepare microparticles or beads to increase the particle size of the spray. The microparticles or beads can be coated. Colorants and flavoring agents can also be added. Table 43 lists examples of prepared fasudil spray formulations.

[0271] Table 43

[0272] Element percentage Function Fasudil-resin complex 99.4975 Active substances FD&C Red 0.0025 Colorants Vanilla flavoring 0.5 Flavoring

[0273] The drug resin complex microparticles may be coated to achieve sustained release properties. Table 44 illustrates an example of sustained release fasudil microparticle formulation.

[0274] Table 44

[0275] Element percentage Function Fasudil-resin complex 92.5 Active substances Ethyl cellulose 10.0 Sustained release coating Polyvinyl alcohol 2.5 Pore ​​former alcohol Appropriate amount to prepare dispersion Coating solvent

[0276] Dispersions of ethylcellulose and polyvinyl alcohol in alcohol can be prepared. The dispersion can be sprayed on the drug-resin particles in a fluidized bed dryer. The particles can be coated and dried simultaneously. Polyvinyl alcohol acts as a pore former and helps to slowly release the drug. Various types of coatings can be used to provide controlled release of the drug from the drug-resin particles. Lactose, sugar, sorbitol powder, etc. can be used instead of polyvinyl alcohol as a pore former.

[0277] To produce microparticles of fasudil resin complex, the following procedure was used. Two grams of HCl fasudil hemihydrate was dissolved in 20 mL of water, to which 1 gram, 2 grams or 4 grams of resin IRP 64 were added. The pH was adjusted to 6.5 with hydrochloric acid. The composition was stirred and the pH was adjusted until the pH was consistent. The resin was then filtered and dried. The resulting drug-resin complexes contained 60%, 50% and 33% of the drug, respectively. The drug loading in the drug-resin complex can be further increased by increasing the input drug:resin ratio.

[0278] Example 14

[0279] Produce a powder for suspension. The drug-resin complex can be further formulated to provide a powder for a suspension formulation. In this case, the powder formulation can be added to water to form a suspension. The drug-resin complex is insoluble in water. The formulation thickens the water so as to suspend the drug-resin particles. The powder used for the suspension drug product dosage form contains a suspending agent and may contain a sweetener, a flavoring agent, and a coloring agent. A preservative may be added so that the suspension is stable in a short time (such as one day to four weeks). A lubricant may be added to help the powder flow and mix. Table 45 lists examples of the composition of the powder for the suspension formulation. When 20 mL and 50 mL of water were added to formulations 1 and 2, respectively, the IDDSI flow test result of the resulting suspension was level 2. The powder may be filled in a glass / plastic bottle or may be supplied in a bag.

[0280] Table 45

[0281] Element Preparation 1 (w / w%) Preparation 2 (w / w%) Function Drug-resin complex 70.2 46.0 Active substances Gellan Gum 17.5 32.2 Suspension Microcrystalline Cellulose 7.0 11.5 Suspension Sucralose 5.2 10.3 Sweeteners

[0282] Example 15

[0283] Fast disintegrating tablets can be produced according to the present disclosure. Fast disintegrating tablets (FDT) are another dosage form suitable for patients with dysphagia. The tablet will disintegrate rapidly when a small amount of water is added to a spoon or other container, or when placed in the mouth without adding water. The FDT can be, for example, an orally disintegrating tablet (ODT).

[0284] Fast disintegrating tablets can be produced by conventional processes, for example, dry / wet granulation, direct compression, etc. Table 46 lists examples of some FDT formulations prepared according to the present disclosure. The resulting tablets disintegrate within one minute. Formulation 9 is an example of ODT.

[0285] Table 46

[0286] series# 6H 9 F16a F16b F30a F30b Element w / w% w / w% w / w% w / w% w / w% w / w% Drug resin complex 40 50.0 50 50.0 50 50 Sodium starch glycolate 0 16.7 16.7 16.7 10 10 KOLLIDON 90F 0 0 20.8 20.8 20 20 HPMC(MHPC 50) 20 0 0 0 0 0 HPMC(E5) 0 16.7 0 0 0 0 Gellan Gum 0 0 0 0 5 5 Xanthan gum 0 0 0 0 0.4 0.4 Microcrystalline Cellulose 40 16.7 12.5 0 14.6 0 LUDIFLASH 0 0 0 12.5 0 14.6

[0287] Example 16

[0288] Effervescent tablets (ET) are another example of solid dosage forms that can be produced according to the present disclosure. Fasudil drug-resin complexes can be incorporated into effervescent tablets. Table 47 lists examples of compositions of fasudil effervescent tablets by weight percentage prepared according to the present disclosure.

[0289] Table 47

[0290] Element percentage Function Drug-resin complex 52.1 Active substances Sodium starch glycolate 8.3 Disintegrants Kollidon 90F 9.4 Adhesives Gellan Gum 5.2 Adhesives Microcrystalline Cellulose 3.8 Adhesives LUDIFLASH 10.6 Thinner Anhydrous citric acid 4.7 Effervescent Sodium bicarbonate 5.7 Effervescent Magnesium Stearate 0.2 Lubricants

[0291] Effervescent tablets can be prepared by conventional methods. The above examples are prepared by dry granulation and compression. Effervescence helps disintegrate the tablet.

[0292] Example 17

[0293] Chewable tablets are examples of solid dosage forms that may be produced. Resins readily absorb water and swell. Therefore, the % resin used in chewable tablets may be less than 20%. Table 48 lists examples of compositions of chewable fasudil tablets that may be produced according to the present disclosure. For example, chewable tablets may be prepared by a wet granulation process.

[0294] Table 48

[0295] Element percentage Function Drug-resin complex 20 Active substances Maltodextrin 30.2 Thinner Mannitol 26.6 Thinner Microcrystalline Cellulose 4.8 Adhesives Croscarmellose Sodium 5 Adhesives Corn starch 4.5 Adhesives Aspartame 0.1 Sweeteners Grape flavoring 0.5 Flavoring Magnesium Stearate 0.3 Lubricants The remaining water in the mixture ~8 Process Assistance

[0296] The present disclosure includes the following aspects / embodiments / features in any order and / or in any combination:

[0297] 1. An oral pharmaceutical composition comprising:

[0298] A rho kinase inhibitor selected from the group consisting of fasudil, a pharmaceutically acceptable salt thereof, a hydrate thereof, a prodrug thereof, a substituted derivative thereof, a metabolite thereof, and any combination thereof; and

[0299] Ion exchange resin.

[0300] 2. The oral pharmaceutical composition according to any preceding or following embodiment / feature / aspect, wherein the ratio of exchange resin to fasudil is about 2.5:1 to about 4.5:1 (w / w).

[0301] 3. The oral pharmaceutical composition according to any preceding or following embodiment / feature / aspect, which is packaged into a unit dose, wherein the unit dose contains about 60 mg to about 180 mg of fasudil.

[0302] 4. The oral pharmaceutical composition according to any preceding or following embodiment / feature / aspect, wherein the ion exchange resin is a first taste-masking agent, and the oral pharmaceutical composition further comprises a second taste-masking agent.

[0303] 5. The oral pharmaceutical composition according to any preceding or following embodiment / feature / aspect, which is formulated into dry powder, microparticles or beads.

[0304] 6. The oral pharmaceutical composition according to any preceding or following embodiment / feature / aspect, wherein the second taste-masking agent comprises one or both of a sweetener and a flavoring agent.

[0305] 7. The oral pharmaceutical composition according to any preceding or following embodiment / feature / aspect, wherein at least 50% of the rho kinase inhibitor is bound to the ion exchange resin.

[0306] 8. The oral pharmaceutical composition according to any preceding or following embodiment / feature / aspect, further comprising a coating on the rho kinase inhibitor and the ion exchange resin.

[0307] 9. An oral pharmaceutical composition according to any preceding or following embodiment / feature / aspect, wherein the coating comprises an enteric coating or a modified release coating, or both.

[0308] 10. The oral pharmaceutical composition according to any preceding or following embodiment / feature / aspect, wherein the coating comprises a taste-masking agent.

[0309] 11. The oral pharmaceutical composition according to any preceding or following embodiment / feature / aspect, comprising a plurality of particles comprising the rho kinase inhibitor and the ion exchange resin.

[0310] 12. The oral pharmaceutical composition according to any preceding or following embodiment / feature / aspect, further comprising a coating covering the plurality of particles.

[0311] 13. The oral pharmaceutical composition according to any preceding or following embodiment / feature / aspect, wherein the ion exchange resin comprises a cation exchange resin.

[0312] 14. The oral pharmaceutical composition according to any preceding or following embodiment / feature / aspect, wherein the cation exchange resin comprises a copolymer of methacrylic acid and divinylbenzene.

[0313] 15. The oral pharmaceutical composition according to any preceding or following embodiment / feature / aspect, wherein the cation exchange resin comprises polacrilin.

[0314] 16. The oral pharmaceutical composition according to any preceding or following embodiment / feature / aspect, wherein the ratio of the ion exchange resin to the rho kinase inhibitor is from about 10:1 to about 1:10.

[0315] 17. The oral pharmaceutical composition according to any preceding or following embodiment / feature / aspect, further comprising a gum, a humectant, a chelating agent, an antioxidant or a preservative, or any combination thereof.

[0316] 18. The oral pharmaceutical composition according to any preceding or following embodiment / feature / aspect, wherein the oral pharmaceutical composition is formulated into a solid dosage form.

[0317] 19. The oral pharmaceutical composition according to any preceding or following embodiment / feature / aspect, wherein the solid dosage form is formulated for absorption of the rho kinase inhibitor in the patient's oral cavity, intestinal tract, or both.

[0318] 20. The oral pharmaceutical composition according to any preceding or following embodiment / feature / aspect, wherein the solid dosage form comprises powder, microparticles or film, or any combination thereof.

[0319] 21. The oral pharmaceutical composition according to any preceding or following embodiment / feature / aspect, wherein the solid dosage form comprises a tablet or a capsule, or both.

[0320] 22. An oral pharmaceutical composition according to any preceding or following embodiment / feature / aspect, wherein the tablet comprises a buccal tablet, a sublingual tablet, a chewable tablet, a fast-dissolving tablet, an effervescent tablet, an orally disintegrating tablet or a lozenge, or any combination thereof.

[0321] 23. The oral pharmaceutical composition according to any preceding or following embodiment / feature / aspect, wherein said solid dosage form comprises about 25 mg to about 170 mg of said rho kinase inhibitor.

[0322] 24. The oral pharmaceutical composition according to any preceding or following embodiment / feature / aspect, wherein the oral pharmaceutical composition can be converted from a solid dosage form to an aqueous composition.

[0323] 25. The oral pharmaceutical composition according to any preceding or following embodiment / feature / aspect, wherein the oral pharmaceutical composition is a unit dose of a non-liquid pharmaceutical composition, the unit dose comprising between 60 mg and 180 mg of fasudil hydrochloride hemihydrate and about 150 mg to about 810 mg of a cation exchange resin.

[0324] 26. The oral pharmaceutical composition according to any preceding or following embodiment / feature / aspect, wherein the unit dose comprises about 150 mg to about 630 mg of a cation exchange resin.

[0325] 27. The oral pharmaceutical composition according to any preceding or following embodiment / feature / aspect, wherein the rho kinase inhibitor is present in an amount sufficient to treat a neurodegenerative disease.

[0326] 28. An oral pharmaceutical composition according to any preceding or following embodiment / feature / aspect, wherein the neurodegenerative disease comprises Alzheimer's disease, vascular dementia, amyotrophic lateral sclerosis (ALS), motor neuron disease, Parkinson's disease, Huntington's disease, multiple sclerosis, progressive supranuclear palsy (PSP) or corticobasal syndrome (CBS), or any combination thereof.

[0327] 29. A method of treating a neurodegenerative disease, the method comprising administering to a patient a composition according to any preceding or following embodiment / feature / aspect in an amount sufficient to treat the neurodegenerative disease.

[0328] 30. The method according to any preceding or following embodiment / feature / aspect, wherein the composition is administered by mixing the composition with food or beverage or both prior to ingestion by the patient.

[0329] 31. An oral pharmaceutical composition comprising:

[0330] fasudil, hydroxyfasudil, or both; and

[0331] Ion exchange resin.

[0332] 32. The oral pharmaceutical composition according to any preceding or following embodiment / feature / aspect, wherein the ratio of exchange resin to fasudil, hydroxyfasudil or both is about 2.5:1 to about 4.5:1 (w / w).

[0333] 33. The oral pharmaceutical composition according to any preceding or following embodiment / feature / aspect, which is packaged into a unit dose, wherein the unit dose contains about 60 mg to about 180 mg of fasudil, hydroxyfasudil, or both.

[0334] 34. The oral pharmaceutical composition according to any preceding or following embodiment / feature / aspect, wherein at least 50% of the fasudil, hydroxyfasudil or both are bound to the ion exchange resin.

[0335] 35. The oral pharmaceutical composition according to any preceding or following embodiment / feature / aspect, further comprising a coating on said fasudil, hydroxyfasudil or both and said ion exchange resin.

[0336] 36. The oral pharmaceutical composition according to any preceding or following embodiment / feature / aspect, comprising a plurality of particles comprising said fasudil, hydroxyfasudil or both and said ion exchange resin.

[0337] 37. The oral pharmaceutical composition according to any preceding or following embodiment / feature / aspect, wherein the ratio of the ion exchange resin to the fasudil, hydroxyfasudil, or both is from about 10:1 to about 1:10.

[0338] 38. The oral pharmaceutical composition according to any preceding or following embodiment / feature / aspect, wherein the solid dosage form is formulated for absorption of the fasudil, hydroxyfasudil, or both in the patient's oral cavity, intestinal tract, or both.

[0339] 39. The oral pharmaceutical composition according to any preceding or following embodiment / feature / aspect, wherein said solid dosage form comprises about 25 mg to about 170 mg of said fasudil, hydroxyfasudil, or both.

[0340] 40. The oral pharmaceutical composition according to any preceding or following embodiment / feature / aspect, wherein the oral pharmaceutical composition is a unit dose of a non-liquid pharmaceutical composition comprising between 60 mg and 180 mg of fasudil, hydroxyfasudil or both and about 150 mg to about 810 mg of a cation exchange resin.

[0341] 41. The oral pharmaceutical composition according to any preceding or following embodiment / feature / aspect, wherein fasudil, hydroxyfasudil or both are present in an amount sufficient to treat a neurodegenerative disease.

[0342] 42. An oral pharmaceutical composition comprising:

[0343] A rho kinase inhibitor, a pharmaceutically acceptable salt thereof, a hydrate thereof, a prodrug thereof, a substituted derivative thereof, or a metabolite thereof, or any combination thereof; and

[0344] Ion exchange resin.

[0345] All references cited or otherwise mentioned in this specification are incorporated herein by reference in their entirety for any relevant aspects of the present disclosure. Variations of the embodiments described herein are also a part of the present disclosure. One or more elements of an embodiment can be combined with one or more elements of another embodiment while still falling within the present disclosure. The order of steps can change while still falling within the present disclosure. The amounts, percentages and ratios described herein can change while still falling within the present disclosure. The range between any two values ​​described herein and any intermediate values ​​also fall within the present disclosure. The equivalents of the embodiments described herein fall within the present disclosure.

Claims

1. An oral pharmaceutical composition comprising: A rho kinase inhibitor selected from the group consisting of fasudil, a pharmaceutically acceptable salt thereof, a hydrate thereof, a prodrug thereof, a substituted derivative thereof, a metabolite thereof, and any combination thereof; and Ion exchange resin.

2. The oral pharmaceutical composition according to claim 1, wherein the ratio of exchange resin to fasudil is about 2.5:1 to about 4.5:1 (w / w).

3. The oral pharmaceutical composition according to claim 1, which is packaged into a unit dose, wherein the unit dose contains about 60 mg to about 180 mg of fasudil.

4. The oral pharmaceutical composition according to claim 3, wherein the ion exchange resin is a first taste masking agent, and the oral pharmaceutical composition further comprises a second taste masking agent.

5. The oral pharmaceutical composition according to claim 4, which is formulated into dry powder, microparticles or beads. The oral pharmaceutical composition according to claim 4 , wherein the second taste-masking agent comprises one or both of a sweetener and a flavoring agent.

7. The oral pharmaceutical composition of claim 1, wherein at least 50% of the rho kinase inhibitor is bound to the ion exchange resin.

8. The oral pharmaceutical composition according to claim 1, further comprising a coating on the rho kinase inhibitor and the ion exchange resin.

9. The oral pharmaceutical composition of claim 8, wherein the coating comprises an enteric coating or a modified release coating, or both.

10. The oral pharmaceutical composition of claim 8, wherein the coating comprises a taste masking agent.

11. The oral pharmaceutical composition according to claim 1, comprising a plurality of particles comprising the rho kinase inhibitor and the ion exchange resin. 12 . The oral pharmaceutical composition according to claim 11 , further comprising a coating covering the plurality of particles.

13. The oral pharmaceutical composition of claim 1, wherein the ion exchange resin comprises a cation exchange resin.

14. The oral pharmaceutical composition according to claim 13, wherein the cation exchange resin comprises a copolymer of methacrylic acid and divinylbenzene.

15. The oral pharmaceutical composition of claim 13, wherein the cation exchange resin comprises polacrilin.

16. The oral pharmaceutical composition of claim 1, wherein the ratio of the ion exchange resin to the rho kinase inhibitor is from about 10:1 to about 1:

10.

17. The oral pharmaceutical composition according to claim 1, further comprising a gum, a humectant, a chelating agent, an antioxidant or a preservative, or any combination thereof.

18. The oral pharmaceutical composition according to claim 1, wherein the oral pharmaceutical composition is formulated into a solid dosage form.

19. The oral pharmaceutical composition of claim 18, wherein the solid dosage form is formulated for absorption of the rho kinase inhibitor in the patient's oral cavity, intestinal tract, or both.

20. The oral pharmaceutical composition according to claim 18, wherein the solid dosage form comprises powder, microgranules or film, or any combination thereof.

21. The oral pharmaceutical composition of claim 18, wherein the solid dosage form comprises a tablet or a capsule, or both.

22. The oral pharmaceutical composition according to claim 21, wherein the tablet comprises a buccal tablet, a sublingual tablet, a chewable tablet, a fast-dissolving tablet, an effervescent tablet, an orally disintegrating tablet or a lozenge, or any combination thereof.

23. The oral pharmaceutical composition of claim 18, wherein the solid dosage form comprises about 25 mg to about 170 mg of the rho kinase inhibitor.

24. The oral pharmaceutical composition of claim 1, wherein the oral pharmaceutical composition is convertible from a solid dosage form to an aqueous composition.

25. The oral pharmaceutical composition according to claim 1, wherein the oral pharmaceutical composition is a unit dose non-liquid pharmaceutical composition comprising between 60 mg and 180 mg of fasudil hydrochloride hemihydrate and about 150 mg to about 810 mg of a cation exchange resin.

26. The oral pharmaceutical composition of claim 25, wherein the unit dose comprises about 150 mg to about 630 mg of a cation exchange resin.

27. The oral pharmaceutical composition of claim 1, wherein the rho kinase inhibitor is present in an amount sufficient to treat a neurodegenerative disease.

28. The oral pharmaceutical composition of claim 27, wherein the neurodegenerative disease comprises Alzheimer's disease, vascular dementia, amyotrophic lateral sclerosis (ALS), motor neuron disease, Parkinson's disease, Huntington's disease, multiple sclerosis, progressive supranuclear palsy (PSP) or corticobasal syndrome (CBS), or any combination thereof.

29. A method of treating a neurodegenerative disease, the method comprising administering to a patient a composition according to claim 27 in an amount sufficient to treat the neurodegenerative disease.

30. The method of claim 29, wherein the composition is administered by mixing the composition with food or beverage, or both, prior to ingestion by the patient.